Unknown.
Australia
Ingredient ID: NPC9891
Ingredient ID: NPC80241
Ingredient ID: NPC80230
Ingredient ID: NPC72046
Ingredient ID: NPC61473
Ingredient ID: NPC59196
Ingredient ID: NPC52968
Ingredient ID: NPC480480
Ingredient ID: NPC480478
Ingredient ID: NPC480477
Ingredient ID: NPC480476
Ingredient ID: NPC43514
Ingredient ID: NPC39884
Ingredient ID: NPC39633
Ingredient ID: NPC278988
Ingredient ID: NPC275150
Ingredient ID: NPC261012
Ingredient ID: NPC238665
Ingredient ID: NPC23336
Ingredient ID: NPC231719
Ingredient ID: NPC230301
Ingredient ID: NPC228469
Ingredient ID: NPC219913
Ingredient ID: NPC213482
Ingredient ID: NPC208553
Ingredient ID: NPC205917
Ingredient ID: NPC203719
Ingredient ID: NPC202463
Ingredient ID: NPC180104
Ingredient ID: NPC177868
Ingredient ID: NPC177476
Ingredient ID: NPC150636
Ingredient ID: NPC149505
Ingredient ID: NPC149203
Ingredient ID: NPC1474
Ingredient ID: NPC145879
Ingredient ID: NPC144054
Ingredient ID: NPC123965
Ingredient ID: NPC121651
Ingredient ID: NPC113550
Ingredient ID: NPC108602
Target Type | Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|---|
Therapeutic Target | Hydrolase | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Therapeutic Target | Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Therapeutic Target | Nuclear hormone receptor subfamily 1 | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
Therapeutic Target | Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Therapeutic Target | Protein Kinase | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
Drug Transporter | SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Drug Transporter | SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
Therapeutic Target | Structural protein | TUBB3 | Tubulin beta-3 chain | Q13509 | CHEMBL2597 |
Therapeutic Target | Structural protein | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Therapeutic Target | Unclassified protein | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
Therapeutic Target | Unclassified protein | GMNN | Geminin | O75496 | CHEMBL1293278 |
Clinical trials associated with plant from natural product (NP) & plant level:
Clinical trials type | Number of clinical trials | |
---|---|---|
NP level | 2966 | |
NCT ID | Title | Condition | Form in clinical use | Associated by plant or compound |
---|---|---|---|---|
NCT00933374 | Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT04269200 | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer | endometrial neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00028743 | Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02012192 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00019812 | Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01769391 | A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01493843 | Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00126243 | Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma | Lymphoma, AIDS-Related | Doxorubicin (NPC261012) | NP level |
NCT00148317 | Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT01968915 | Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03731442 | Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00580333 | Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02938442 | Vaccination of Triple Negative Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04540211 | A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02754726 | Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT02289456 | Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2 | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05342636 | A Study of Combination Therapies With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer (MK-3475-06A) | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00546156 | Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02845908 | POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01839773 | A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00003397 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00449657 | Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02477826 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02574663 | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | rectum cancer;colorectal carcinoma;gastrointestinal stromal tumor;esophageal cancer;gastric cancer;pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00736944 | Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04243616 | Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01676649 | Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT05173987 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | endometrial neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01413750 | Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00128856 | Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00466960 | Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy | ovarian serous cystadenocarcinoma;endometrioid carcinoma;fallopian tube cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT04548440 | Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00626704 | Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00883116 | A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT00608803 | Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors | cancer | Doxorubicin (NPC261012) | NP level |
NCT05070598 | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT04624984 | PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02300935 | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00014118 | Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT03554044 | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03492047 | N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients | peripheral neuropathy | Paclitaxel (NPC208553) | NP level |
NCT03740165 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT02032277 | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04089150 | MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04001569 | AZD8186 and Paclitaxel in Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT04922567 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00054392 | Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00886717 | Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03801668 | Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT01494688 | A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00006276 | Micellar Paclitaxel to Treat Severe Psoriasis | psoriasis | Paclitaxel (NPC208553) | NP level |
NCT00028860 | Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT00002105 | Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma | Kaposi's sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03742102 | 9-ING-41 in Patients With Advanced Cancers | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02299999 | SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00874107 | Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04516616 | Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer | cervical adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03013218 | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | non-Hodgkins lymphoma | Paclitaxel (NPC208553) | NP level |
NCT01864109 | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | Ewing sarcoma | Doxorubicin (NPC261012) | NP level |
NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00915369 | A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00038246 | Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00110695 | Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01578551 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03002103 | A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00925821 | Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT04757337 | Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00003004 | Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00823186 | Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00002679 | Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04632992 | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | cancer | Paclitaxel (NPC208553) | NP level |
NCT03942068 | Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00144053 | A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00617409 | To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003880 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02873598 | A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05371301 | Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01809379 | Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT05427383 | KN026 in Combination With Chemotherapy in the Second Line Treatment of HER-2 Positive Advanced or Metastatic Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00129727 | Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00661193 | S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00005584 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00933387 | A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma | mouth neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00568464 | Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT) | Ewing sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03126708 | Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT05145218 | Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01822756 | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00198367 | Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00479817 | Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02468557 | Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003733 | Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT04569032 | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03164993 | Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00201734 | Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary | adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00006374 | Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04638790 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05095467 | HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction | stomach neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01148446 | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01148628 | Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors | neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00003342 | Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT03393884 | A Study of Apatinib Treatment in for Advanced Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02383251 | Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01666418 | Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel | melanoma | Paclitaxel (NPC208553) | NP level |
NCT03432598 | Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00226746 | Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00877071 | LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT03544567 | A Study of Oraxol in Subjects With Cutaneous Angiosarcoma | angiosarcoma | Paclitaxel (NPC208553) | NP level |
NCT01253681 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02506777 | Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer. | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03498521 | Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT00095914 | Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00871013 | Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00030368 | Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02845882 | LBL-2016 for Children or Adolescents in China | lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01649336 | A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT01935492 | 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02241551 | Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00770809 | Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01031212 | ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03606967 | Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00603538 | Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00539331 | Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04761601 | First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00083551 | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT04224337 | Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma | non-small cell lung carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00230451 | Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02865811 | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Doxorubicin (NPC261012) | NP level |
NCT00486759 | A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
NCT04931342 | Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03328234 | Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03 | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02608229 | BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01285466 | A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01622361 | Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00748553 | A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05404945 | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00708812 | Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00589238 | Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03329378 | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02630264 | E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck | upper aerodigestive tract neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00581776 | Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02017015 | Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer | pancreatic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02744898 | A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00434135 | Alimta and Gemcitabine in Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00001384 | A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01871766 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | rhabdomyosarcoma | Doxorubicin (NPC261012) | NP level |
NCT04723030 | The Transformation of Locally Advanced Pancreatic Cancer. | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03129828 | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03830606 | The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma | biliary tract cancer | Paclitaxel (NPC208553) | NP level |
NCT00081302 | Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | lung neoplasm;metastasis;kidney cancer | Doxorubicin (NPC261012) | NP level |
NCT03345810 | Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) | large cell lung carcinoma;lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03336216 | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01014767 | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors | brain cancer;choroid plexus neoplasm | Doxorubicin (NPC261012) | NP level |
NCT03937830 | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01704716 | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | neuroblastoma | Doxorubicin (NPC261012) | NP level |
NCT02122770 | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02605694 | Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03225924 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003230 | Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia | leukemia | Paclitaxel (NPC208553) | NP level |
NCT00189553 | Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT03025477 | Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01929941 | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies | Hodgkins lymphoma | Paclitaxel (NPC208553) | NP level |
NCT02429700 | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors | ovarian sex cord-stromal tumor | Paclitaxel (NPC208553) | NP level |
NCT02366143 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00399126 | Phase I Trial of Paclitaxel With Perifosine | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01179269 | Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04177108 | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04594798 | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01172223 | Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04478292 | A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy | Hepatoblastoma | Doxorubicin (NPC261012) | NP level |
NCT02481635 | A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00189566 | Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | fallopian tube cancer;ovarian cancer;peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03853707 | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003595 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003944 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00661167 | Phase II Study of ABI-007 for Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00191789 | Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00452803 | Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC) | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00506155 | Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
NCT04581876 | The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01069328 | Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00808899 | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
NCT04032964 | Dose Finding Study of L19TNF and Doxorubicin in Patients With STS | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT02593175 | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00129922 | Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04594005 | CDK4/6 Tumor, Abemaciclib, Paclitaxel | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00513292 | Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02525653 | Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03808480 | Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% | non-small cell lung carcinoma | Doxorubicin (NPC261012) | NP level |
NCT03192644 | The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01612351 | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03542266 | CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02838225 | DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02924909 | Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT03306121 | TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01493310 | Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00001498 | A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03563170 | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | hepatocellular carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00971841 | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02834975 | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT05075460 | Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00691379 | Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05168527 | The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01752205 | Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01088815 | Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00002937 | Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04238988 | Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00407888 | Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01804127 | Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02730481 | A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00009750 | Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT05294900 | Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05159193 | Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04027764 | Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer | biliary tract cancer | Paclitaxel (NPC208553) | NP level |
NCT01279291 | Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT00022191 | Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer | urethra cancer;urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT01168791 | Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT01240629 | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | prostate cancer | Doxorubicin (NPC261012) | NP level |
NCT02283489 | Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors | upper aerodigestive tract neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01424982 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Doxorubicin (NPC261012) | NP level |
NCT03940001 | A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01840592 | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT04865289 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study | endometrial neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03596281 | Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT02116530 | Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy | Nausea and vomiting | Doxorubicin (NPC261012) | NP level |
NCT00329641 | Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00844649 | Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01992341 | AMG 386 Drug-Drug Interaction Study With Paclitaxel | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00431795 | Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02005315 | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00816959 | Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00581971 | Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer | cancer | Paclitaxel (NPC208553) | NP level |
NCT02588443 | Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01621243 | M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04888663 | Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study) | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01579578 | Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer | cancer | Paclitaxel (NPC208553) | NP level |
NCT00176254 | Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04004871 | Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00002917 | Paclitaxel in Treating Patients With Early-Stage Bladder Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT01688791 | Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | cancer | Paclitaxel (NPC208553) | NP level |
NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT03718624 | A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01516580 | Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients | leukemia;non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00310011 | Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT00057928 | S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT02420314 | Pharmacological Ascorbate for Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00248248 | DOXIL for Consolidation Therapy in Ovarian Cancer. | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
NCT04023916 | Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00511849 | Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00050167 | Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00801736 | ERCC1 Targeted Trial | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01862081 | A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00003394 | Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00144807 | ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01248403 | A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00625573 | Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01) | colorectal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00476827 | A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03169777 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | colorectal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01670500 | Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00323323 | CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01514188 | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00583349 | Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT01653470 | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens | cancer | Paclitaxel (NPC208553) | NP level |
NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00005646 | Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00476190 | ALL Adult Consortium Trial: Adult ALL Trial | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT01838538 | Abraxane/Bevacizumab | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01056679 | Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00006377 | Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT01351350 | Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT00003578 | High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00851877 | Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT04301739 | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02275598 | Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02605915 | Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02835586 | STREAMER : STent Restenosis And MEdicaments Release | ischemia | Paclitaxel (NPC208553) | NP level |
NCT02379416 | Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01185964 | A Study of Olaratumab in Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00039039 | Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02073968 | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00149214 | Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00174707 | Study of Docetaxel in Breast Cancer Patients | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT05406401 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00042835 | Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer | lung adenocarcinoma;squamous cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04148911 | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03029611 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT04060459 | Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT00718484 | A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03475615 | A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02475772 | A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT01593228 | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Doxorubicin (NPC261012) | NP level |
NCT04563975 | Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00003117 | Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02640755 | Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer | cancer | Paclitaxel (NPC208553) | NP level |
NCT00567554 | Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00048893 | Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer | metastasis;breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00006929 | Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05210374 | Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03758989 | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00520013 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02787239 | Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
NCT00709761 | Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00193297 | Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02784288 | Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00204568 | Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS) | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT04047004 | Adjuvant PIPAC in Gastric Cancer Patients | gastric adenocarcinoma | Doxorubicin (NPC261012) | NP level |
NCT01258192 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02976909 | Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04882462 | Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00290537 | Phase II Study of ZD6474 in Advanced NSCLC | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00174655 | BIG 02/98 Docetaxel - Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT05100628 | A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT02891083 | Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03417921 | A Study of ABTL0812 in Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03694002 | Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery | Thymic Carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00770224 | S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02124317 | Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00193037 | Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00003399 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma | multiple myeloma | Paclitaxel (NPC208553) | NP level |
NCT00169130 | ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00326456 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT00437749 | A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00542451 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03719430 | APX005M and Doxorubicin in Advanced Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT01652261 | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04164368 | Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00439296 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | childhood acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00005581 | Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02138812 | A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT01271725 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04081389 | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | breast carcinoma in situ | Doxorubicin (NPC261012) | NP level |
NCT00035152 | Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01374620 | Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel | cancer | Paclitaxel (NPC208553) | NP level |
NCT02207465 | A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00801580 | My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia | lymphoid leukemia | Doxorubicin (NPC261012) | NP level |
NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT01851174 | Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02617849 | Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00496028 | Phase I Study in Patients With Solid Tumours | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00838656 | Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT03519308 | A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01281150 | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01831505 | Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02531308 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03197935 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00289263 | Maintenance Chemotherapy in Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02622074 | Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT01336062 | Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00350025 | Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00003899 | Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00652119 | Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00365365 | Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00877006 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00288431 | Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT01779050 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT02784015 | Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00800202 | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003127 | S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT02897700 | A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00736320 | HD16 for Early Stage Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00004159 | Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01839487 | PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04139304 | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00617591 | Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT04195828 | Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT03314740 | Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03248427 | Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT05316376 | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00004031 | SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00968253 | RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00170664 | Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT05394415 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05489848 | Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00003624 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | cervical cancer;endometrial cancer;fallopian tube cancer;ovarian cancer;peritoneum cancer;sarcoma | Paclitaxel (NPC208553) | NP level |
NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT02016209 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03507491 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | cancer | Paclitaxel (NPC208553) | NP level |
NCT03322566 | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00147680 | Uterine Papillary Serous Cancer (UPSC) Trial | uterine cancer | Paclitaxel (NPC208553) | NP level |
NCT00002894 | Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00546156 | Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05420636 | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01820754 | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | inflammatory breast carcinoma | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT01333423 | Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC) | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00780039 | A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00340184 | A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00005028 | Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT02359162 | Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00394082 | ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01366131 | Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00515073 | Papillary Serous Carcinoma of the Endometrium | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT05281003 | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00477412 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04223024 | Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01558492 | Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00002587 | Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02412371 | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00807859 | Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00121992 | Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT02152137 | Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer | thyroid cancer | Paclitaxel (NPC208553) | NP level |
NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | acute myeloid leukemia;acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT04000295 | An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01285609 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03056001 | Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT02985333 | Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | multiple myeloma | Paclitaxel (NPC208553) | NP level |
NCT01470417 | Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00002662 | Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00003008 | Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma | sarcoma | Paclitaxel (NPC208553) | NP level |
NCT00568451 | Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma | cutaneous melanoma | Paclitaxel (NPC208553) | NP level |
NCT00003622 | Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00483301 | A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT02182232 | A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02753647 | Chidamide Plus R-CHOP in Elderly DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03428425 | A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00087802 | Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00807612 | QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00006120 | Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03328494 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | cancer | Paclitaxel (NPC208553) | NP level |
NCT00093795 | Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02177695 | S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
NCT04675528 | Food Effect on Pharmacokinetics and SafEty of DHP107 (Liporaxel®) FEEL Study | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01246193 | CKD-828(80/2.5mg) Pharmacokinetic Study | hypertension | Paclitaxel (NPC208553) | NP level |
NCT00003957 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00006027 | Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00203372 | Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299) | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04021992 | GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00094835 | Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01797900 | The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | urethra cancer | Paclitaxel (NPC208553) | NP level |
NCT02834975 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT02053597 | TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03308552 | Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02 | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01229930 | Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT02918747 | PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01354522 | TAC Versus TCX as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00401635 | END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin | endometrial cancer | Doxorubicin (NPC261012) | NP level |
NCT00609791 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00544648 | Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02520154 | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT00002565 | Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01444547 | A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and Cisplatin | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT03017326 | Paediatric Hepatic International Tumour Trial | Hepatoblastoma | Doxorubicin (NPC261012) | NP level |
NCT00005046 | Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00002969 | S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT05400915 | Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT05381909 | Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04729387 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT01822496 | Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03496662 | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00006245 | Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00460317 | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04506554 | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | urinary bladder carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01802749 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma | rhabdomyosarcoma | Doxorubicin (NPC261012) | NP level |
NCT02631109 | L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis | hemophagocytic syndrome | Doxorubicin (NPC261012) | NP level |
NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | breast ductal carcinoma in situ | Paclitaxel (NPC208553) | NP level |
NCT00270790 | EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202) | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT01100359 | Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer | endometrial cancer | Doxorubicin (NPC261012) | NP level |
NCT00003054 | Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus | sarcoma | Paclitaxel (NPC208553) | NP level |
NCT00881816 | Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma | gastric carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00016315 | Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00254592 | Neoadjuvant Treatment of Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00768859 | Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02632071 | ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01755897 | A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients | cervical adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT02492503 | Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix | cervical carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04831320 | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00635726 | Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
NCT00003042 | Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03252808 | Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer. | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02379585 | Fasting on Newly Diagnosed Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04428151 | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04617067 | Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00470301 | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00052351 | Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00005847 | Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00002711 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00954512 | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04266249 | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01214668 | Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors | neoplasm | Doxorubicin (NPC261012) | NP level |
NCT02419495 | Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies | Fallopian Tube Carcinoma;ovarian carcinoma | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT00434356 | A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02272790 | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Fallopian Tube Carcinoma;ovarian carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04527991 | Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer | urogenital neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04652076 | GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab | cervical carcinoma;endometrial carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00973752 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00206466 | Biologic Correlative Taxotere/AC | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00486668 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00687687 | Evaluation of Paclitaxel (Taxol, NSC | Uterine Carcinosarcoma | Paclitaxel (NPC208553) | NP level |
NCT00634205 | Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma | mesothelioma | Doxorubicin (NPC261012) | NP level |
NCT05218889 | Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00508326 | Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement | cancer | Paclitaxel (NPC208553) | NP level |
NCT00199758 | Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02317419 | Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer | cancer | Paclitaxel (NPC208553) | NP level |
NCT00369551 | Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer | lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00062062 | Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00523380 | Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT03536039 | RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04862585 | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel | breast carcinoma in situ | Paclitaxel (NPC208553) | NP level |
NCT04825938 | Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms | salivary gland neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01966003 | Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05227664 | A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01730586 | Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas | colorectal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00832494 | Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00526890 | Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT05485766 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | Hereditary breast and ovarian cancer syndrome | Paclitaxel (NPC208553) | NP level |
NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00093145 | Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00003539 | Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02455141 | A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01827111 | Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00004887 | Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03928314 | Study of ORIC-101 in Combination With Anticancer Therapy | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00550771 | Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00455533 | Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04868708 | A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00779714 | Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC | melanoma | Paclitaxel (NPC208553) | NP level |
NCT01328236 | Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia | plasma cell leukemia;multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00100789 | S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00979212 | Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00974324 | Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03834948 | AO-176 in Multiple Solid Tumor Malignancies | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04054362 | Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01340131 | CKD-828 (40/5mg) Pharmacokinetic Study | hypertension | Paclitaxel (NPC208553) | NP level |
NCT00118209 | Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003972 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00041119 | Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04249167 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01701349 | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer | thyroid cancer | Paclitaxel (NPC208553) | NP level |
NCT01352689 | CKD-828(80/2.5mg) Pharmacokinetic Study_2nd | hypertension | Paclitaxel (NPC208553) | NP level |
NCT02212015 | Evaluation of Votrient in Angiosarcoma | angiosarcoma | Paclitaxel (NPC208553) | NP level |
NCT03301350 | Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03394885 | Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2) | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03577704 | The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04196283 | Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors | cancer | Paclitaxel (NPC208553) | NP level |
NCT01746771 | A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00495170 | Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00002819 | Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01649336 | Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03233347 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours | pancreatic ductal adenocarcinoma | Doxorubicin (NPC261012) | NP level |
NCT05422066 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02513563 | AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00005819 | Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01120171 | Myocet Plus Endoxan for Older Patients With Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01009983 | Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01920932 | Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01693276 | Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03071926 | Metronomic PLD in Patients With Primary Endocrine Resistant ABC | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03219762 | Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05272696 | Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02767557 | Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00004094 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT01852435 | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | diffuse large B-cell lymphoma;follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04043494 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma | lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00361621 | Ph II CHOP+Velcade in Mediastinal LBCL | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03802071 | A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT01357161 | Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03989336 | Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT04895358 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00945724 | Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00976573 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma | cutaneous melanoma | Paclitaxel (NPC208553) | NP level |
NCT05453500 | Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00003782 | Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00637897 | Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04278287 | Chemoradiotherapy in Unresectable Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02250599 | Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00441168 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00006256 | Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01788137 | A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients | T-cell acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT04506138 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00584857 | A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer | uterine cancer | Paclitaxel (NPC208553) | NP level |
NCT00521781 | Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer | prostate adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00151060 | Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00136565 | Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00201435 | Wkly Taxol x 12 | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00088114 | STA-4783 and Paclitaxel for Treatment of Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00194792 | Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00391118 | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | Fallopian Tube Carcinoma;ovarian cancer;peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00004865 | Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT03396445 | Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00004253 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00825201 | A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00004979 | Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00576225 | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00274456 | Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00789581 | A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00193531 | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma | neuroendocrine carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00785291 | Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00307255 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00768469 | Study Evaluating Safety And Tolerability, Solid Tumor | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05244993 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT02930902 | Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00525642 | Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00787852 | A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05247619 | A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT04572100 | Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer | oropharynx squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03400306 | A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer | ovarian carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00373217 | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00549848 | Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT02050178 | Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00504504 | Rituximab and ABVD for Hodgkin's Patients | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02505269 | Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00186849 | Therapy for Children With Advanced Stage High Risk Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
NCT00001450 | Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01440088 | A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT01506973 | A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer | adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00618657 | Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00394251 | Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00038168 | Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT02106884 | Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00004067 | Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04046016 | A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00653939 | A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01358071 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00005806 | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00442260 | Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03033914 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04883281 | A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer | ovarian carcinoma | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT00003742 | Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00023673 | Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01783535 | Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma | retinoblastoma | Doxorubicin (NPC261012) | NP level |
NCT00165178 | Treatment of Acute Lymphoblastic Leukemia in Children | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT03038100 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00881101 | Clinical Study of Liposomal Paclitaxel in Chinese Patients | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00054665 | PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
NCT00041470 | Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04190745 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01414855 | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01224652 | Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00196872 | A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN) | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00970580 | A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00038402 | Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00079287 | Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT05491694 | To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00154726 | Paclitaxel-HDFL for Locally Advanced and Recurrent/Metastatic Gastric Cancers | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00729612 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00312208 | Docetaxel in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00687440 | Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT05235542 | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT00201708 | Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00756470 | Phase II Neoadjuvant in Inflammatory Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01303497 | Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas | angiosarcoma | Paclitaxel (NPC208553) | NP level |
NCT03029611 | Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02012088 | Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02733380 | Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01739894 | Feasibility Study of Intraperitoneal Paclitaxel | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02812654 | Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT01362374 | Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02125513 | Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer | Fallopian Tube Carcinoma;peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03057366 | A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00997009 | Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT02948075 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02451956 | Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT03880695 | Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00228319 | Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01705158 | Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT02562378 | T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00031876 | Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03420014 | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
NCT00846027 | A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03081143 | Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy | gastric carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02159820 | Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00787527 | SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05367206 | Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00848718 | A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04526470 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00532857 | Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04390958 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00124943 | Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis | Coronary Restenosis | Paclitaxel (NPC208553) | NP level |
NCT01654146 | Dose-finding Study in Platinum-Resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00119262 | Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02060253 | Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00193440 | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003862 | Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02256436 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | urogenital neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00448305 | Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03464734 | Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma | urothelial carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00178256 | Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01248949 | A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00215943 | Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study | rhabdomyosarcoma | Doxorubicin (NPC261012) | NP level |
NCT01402271 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT01523977 | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT02879513 | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | inflammatory breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05099666 | Lurbinectedin + Doxorubicin In Leiomyosarcoma | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
NCT02050009 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT04322318 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | kidney Wilms tumor | Doxorubicin (NPC261012) | NP level |
NCT01911598 | A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT04937673 | The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02383212 | Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel | cancer | Paclitaxel (NPC208553) | NP level |
NCT01057069 | Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00194779 | Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00154700 | Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT04714190 | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression | gastric carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00322452 | First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00491855 | Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis | peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02445404 | Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01205217 | Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01081951 | Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01272557 | Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial | carcinoma of liver and intrahepatic biliary tract | Doxorubicin (NPC261012) | NP level |
NCT03165994 | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00009932 | Combination Chemotherapy in Treating Patients With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03912402 | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA) | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT01572038 | LUX-Breast 2 | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02312661 | Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04874311 | Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00882973 | Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04006041 | Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00544232 | Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02593708 | Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05493995 | A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. | pancreatic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04672005 | Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00020449 | Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | sarcoma | Paclitaxel (NPC208553) | NP level |
NCT00750386 | An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT04780464 | A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00752115 | Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05189730 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00505492 | Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy | uterine neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05145569 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01583426 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) | inflammatory breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03085056 | Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | thyroid cancer | Paclitaxel (NPC208553) | NP level |
NCT04546620 | Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02723955 | Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02449265 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02382263 | Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01560104 | A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00077220 | Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma | lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00536393 | Treatment of Disseminated High Grade Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC | lung adenocarcinoma;squamous cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03852979 | Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT01974440 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03534713 | Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00176267 | Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03497702 | Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02228772 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | B-cell acute lymphoblastic leukemia;lymphoblastic lymphoma;T-cell acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT04864782 | QL1604 Plus Chemotherapy Versus Chemotherapy in Subjects With Stage ⅣB, Recurrent, or Metastatic Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00002707 | Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT05024773 | Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) | urinary bladder carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05383196 | Onvansertib + Paclitaxel In TNBC | inflammatory breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05222204 | DDP ip Combined With AG in PDAC With Peritoneal Metastasis | pancreatic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00003350 | Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma | Kaposi's sarcoma | Paclitaxel (NPC208553) | NP level |
NCT00777673 | Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02117024 | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01622439 | Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03539328 | Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00129389 | FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00655876 | Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT01332968 | A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00806286 | Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01159418 | LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03169790 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | non-Hodgkins lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00479674 | Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | inflammatory breast carcinoma;male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01893801 | Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03850769 | Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00993655 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT05298020 | Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00110084 | ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03286244 | Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT05006664 | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00096668 | Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00003877 | Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04781413 | Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01220128 | Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02399137 | A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03678883 | Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01767155 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer | endometrial cancer | Doxorubicin (NPC261012) | NP level |
NCT01940497 | A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00071188 | ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01998906 | A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02392637 | Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | gallbladder cancer;intrahepatic cholangiocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01966471 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00002717 | Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00002568 | Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02437812 | Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma | ovarian carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00820170 | Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04517435 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00002852 | Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer | lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00795613 | Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003401 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma | multiple myeloma | Paclitaxel (NPC208553) | NP level |
NCT01283204 | Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00993655 | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | fallopian tube cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT04921527 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00097227 | Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003322 | Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT05067530 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01998347 | Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00278122 | Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | cutaneous melanoma | Paclitaxel (NPC208553) | NP level |
NCT00499122 | NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03430882 | Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03193918 | Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00005644 | Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | urethra cancer;urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT00145002 | A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL) | adult T-cell leukemia/lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03725059 | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04004234 | A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC | biliary tract cancer | Paclitaxel (NPC208553) | NP level |
NCT01411410 | Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03805022 | Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | Malignant Bone Neoplasm;malignant glioma;sarcoma | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT01836679 | Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01253681 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04390399 | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02672475 | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00158379 | Taxol Carboplatin and Erythropoetin | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01174238 | A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00124956 | Doxorubicin Pharmacokinetic (PK) Study | cancer | Doxorubicin (NPC261012) | NP level |
NCT00738699 | First Line Tx Stage III Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT05047991 | Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01604863 | A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT04282109 | Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00542191 | Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02867566 | A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00731380 | A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00003242 | Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00083915 | DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT03279237 | A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT01757288 | Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00397761 | Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00003386 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00703170 | Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies | cancer | Doxorubicin (NPC261012) | NP level |
NCT02272738 | A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05204173 | Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00675259 | Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00003379 | Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00334802 | Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01616303 | A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04679064 | Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02926183 | Study of NAC of GA Therapy for Patients With BRPC | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00070564 | S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00146549 | Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04592211 | Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00828841 | Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00702299 | Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT01954355 | Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT05449483 | Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00913835 | A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
NCT04243434 | PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | Abnormality of blood and blood-forming tissues | Doxorubicin (NPC261012) | NP level |
NCT00659178 | Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00033410 | Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00861627 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02276560 | Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00411138 | Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT03806049 | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00748163 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00511459 | Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03023046 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01358747 | Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04002947 | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02057380 | A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01447706 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00655850 | Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01046825 | Mature B-Cell Lymphoma And Leukemia Study III | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00016341 | Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00002734 | Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT01649336 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00003717 | Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00484432 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT01887587 | Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003812 | Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02975141 | Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00781612 | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | metastasis | Paclitaxel (NPC208553) | NP level |
NCT00451178 | A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02997358 | Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
NCT05283226 | Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03036488 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT04943445 | Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers | laryngeal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01206881 | Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01463072 | Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01644825 | A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03815461 | Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00072319 | Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03871036 | Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | urothelial carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003120 | S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | oral squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00574080 | UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT01356680 | HD17 for Intermediate Stage Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01281176 | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03714555 | Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00602797 | Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00809341 | R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01476787 | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00298415 | Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00145639 | Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma | osteosarcoma | Doxorubicin (NPC261012) | NP level |
NCT03272477 | Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05177796 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03918278 | A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00002984 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02220894 | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00547443 | Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01750073 | Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01953536 | Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00052312 | Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00431080 | Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00003591 | Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00583830 | A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02047513 | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00814541 | PAD. ICORG 05-01, V11 | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00791947 | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01569204 | Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02001272 | LDE225 and Paclitaxel in Solid Tumors | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00774826 | Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00069901 | Phase II CT-2103/Carboplatin in Ovarian Cancer | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05270057 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies | Burkitts lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00093444 | Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | liver cancer | Doxorubicin (NPC261012) | NP level |
NCT00006472 | Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT04581343 | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00016900 | PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT04634877 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | endometrial neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00793377 | Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01694576 | NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01441349 | Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00486954 | Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01016054 | A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT02024009 | Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2 | pancreatic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02055820 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00634179 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00626405 | Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery | cutaneous melanoma | Paclitaxel (NPC208553) | NP level |
NCT03748134 | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00773695 | A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00479128 | Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors | urethra cancer | Doxorubicin (NPC261012) | NP level |
NCT00654836 | Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02776917 | Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05112536 | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04661696 | Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT04884035 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00031954 | Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT04766359 | Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04778839 | Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01303926 | Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00004921 | High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00025298 | Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | cholangiocarcinoma;gastric cancer;pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02204345 | A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003587 | S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02560051 | Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer | prostate adenocarcinoma | Doxorubicin (NPC261012) | NP level |
NCT02040454 | Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis (PaciFIST-2) | stricture | Paclitaxel (NPC208553) | NP level |
NCT00502203 | Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus | mixed neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02529852 | A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00456846 | First Line Therapy for Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03609047 | Adjuvant Palbociclib in Elderly Patients With Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00033553 | Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02038621 | The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00014599 | Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva | vulva cancer | Paclitaxel (NPC208553) | NP level |
NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | Burkitts lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT04634539 | Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00481078 | Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00254592 | Neoadjuvant Treatment of Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT05008224 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04745949 | PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
NCT00616967 | Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00550784 | Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00034164 | Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01868984 | Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis | stricture | Paclitaxel (NPC208553) | NP level |
NCT01402271 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT00453323 | Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02051751 | A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer | upper aerodigestive tract neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01964534 | Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05346146 | A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer. | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03421353 | AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02132949 | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00732836 | Hepatic Arterial Infusion (HAI) of Abraxane | liver cancer | Paclitaxel (NPC208553) | NP level |
NCT02573493 | Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00001339 | A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection | carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01818063 | Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | triple-negative breast cancer | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT00466986 | Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01200342 | Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT03907475 | Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03085914 | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer | uterine neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01024712 | Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00887575 | Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01633970 | A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | cancer | Paclitaxel (NPC208553) | NP level |
NCT00140595 | ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02403895 | AZD2014 and Weekly Paclitaxel in Squamous NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01847677 | Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin | ovarian carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00543829 | Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT02297217 | Chemoradiotherapy for Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00068757 | Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02677116 | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | metastasis | Doxorubicin (NPC261012) | NP level |
NCT05002686 | Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00722592 | Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT01711697 | An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00408070 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00093795 | Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00970996 | Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT01253525 | Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas | adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00793897 | Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03008512 | A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib | hepatocellular carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00272987 | Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00937560 | ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03669783 | Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) | childhood kidney neoplasm | Doxorubicin (NPC261012) | NP level |
NCT02995772 | Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02442362 | TOF Versus SOX in Metastatic Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT04625543 | Neoadjuvant Immunotherapy to ESCC | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01488552 | Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02483247 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | cancer | Doxorubicin (NPC261012) | NP level |
NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01160601 | Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00212082 | Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01516567 | Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00161278 | Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00320541 | A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03309150 | ATRi Transition Rollover Study | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01861951 | A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT01270373 | NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After? | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00314977 | Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer. | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04644250 | Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02570711 | Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00503750 | Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™) | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01990352 | Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03755804 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003105 | Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT00002928 | Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00077246 | ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00168883 | Study for Patients With Non Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04527900 | The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT03635567 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00176293 | Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer | prostate cancer | Doxorubicin (NPC261012) | NP level |
NCT00582725 | R-CHOP + GM-CSF for Previously Untreated LCL in Elderly | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01770301 | Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR) | sex cord-gonadal stromal tumor | Paclitaxel (NPC208553) | NP level |
NCT00030654 | Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT03884101 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) | endometrial neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00133302 | Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809) | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02308553 | Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma | cutaneous melanoma | Paclitaxel (NPC208553) | NP level |
NCT00082095 | To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00072215 | Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors | testicular neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02607982 | CCRT for Esophageal Cancer. | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00147225 | AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | cancer | Doxorubicin (NPC261012) | NP level |
NCT04815408 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00876395 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03117933 | Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00231868 | A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma | uterine cancer | Paclitaxel (NPC208553) | NP level |
NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | inflammatory breast carcinoma | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT00723957 | A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00356811 | Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05058404 | Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01796002 | Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00002627 | Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01158144 | Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01285765 | Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02762474 | Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02470585 | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT04150575 | A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT01822613 | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00379574 | Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05498896 | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03348904 | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01650376 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03287271 | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01608009 | [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00194753 | Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00022945 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05170438 | Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment | biliary tract cancer | Paclitaxel (NPC208553) | NP level |
NCT00003402 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | leukemia;lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00533936 | Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00955305 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | large cell lung carcinoma;lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01170663 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00532285 | Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04063683 | Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC). | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00022620 | Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | cervical adenocarcinoma;cutaneous melanoma | Paclitaxel (NPC208553) | NP level |
NCT00009763 | Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02430311 | The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02934464 | Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers | stomach neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00301028 | Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00408408 | Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00001300 | A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT01011075 | Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02520154 | Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03412799 | Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04999969 | Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04084158 | A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03699449 | Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03721744 | A Study of Napabucasin in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04767295 | A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC) | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00855764 | Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT02723994 | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | leukemia | Doxorubicin (NPC261012) | NP level |
NCT00838656 | First Line Tx Stage III Ovarian Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT00022230 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02240212 | A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel. | cancer | Paclitaxel (NPC208553) | NP level |
NCT03086369 | A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05044871 | Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02023710 | Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT01493505 | EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03894540 | Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03020329 | Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04314895 | Trial of NanoPac Intratumoral Injection in Lung Cancer | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05255471 | Antitumor Activity of Neoadjuvant Chemotherapy With or Without BINTRAFUSP ALFA in Patients With Metastatic Advanced Stage Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01333085 | Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT01027910 | PCI-24781 in Combination With Doxorubicin to Treat Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT04742036 | Capivasertib China PK Study | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03047265 | Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00003087 | Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT03316599 | Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01873326 | Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors | germ cell tumor | Paclitaxel (NPC208553) | NP level |
NCT04135781 | Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT04289792 | Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer | pancreatic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04258644 | Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT04979585 | Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00005612 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00138151 | Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00096343 | Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02083679 | Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05054439 | A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00436566 | Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03285607 | MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03705429 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00003284 | High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | non-Hodgkins lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00499018 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00786552 | Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer | thyroid cancer | Paclitaxel (NPC208553) | NP level |
NCT03763123 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02861690 | Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02302807 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT01620190 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04672928 | A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00028769 | S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00933803 | Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00433433 | Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02109445 | Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03647072 | PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04472429 | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02377752 | A Study of Olaratumab in Japanese Participants With Advanced Cancer | neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00881166 | Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors | cancer | Paclitaxel (NPC208553) | NP level |
NCT05193604 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00607048 | Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03263741 | Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01183559 | A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery | esophageal carcinoma;stomach neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00533949 | High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00003701 | Combination Chemotherapy in Treating Patients With Bladder Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT00636441 | Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00454324 | Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01014351 | Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | metastatic melanoma | Paclitaxel (NPC208553) | NP level |
NCT01980810 | First Line Chemotherapy for Advanced Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00536939 | Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00005635 | Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03083470 | Study of SOR007 Ointment for Actinic Keratosis | actinic keratosis | Paclitaxel (NPC208553) | NP level |
NCT00102219 | A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00828009 | BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04035473 | A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04856137 | A Phase I/II Study of Diffuse Large B-cell Lymphoma | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT03435250 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00005026 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00520975 | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00064077 | Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix | cervical adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00686959 | Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00390611 | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00104676 | Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors | teratoma;testicular neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00578149 | Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01978184 | Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05303792 | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02264990 | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02064491 | Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00129389 | FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00585052 | A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03693677 | First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01593306 | Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix | carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02979392 | Phase I Study of TENPA in Advanced Solid Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01468740 | Prospective Study on HIV-related Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00046514 | ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer | metastasis;breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01034189 | Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT01171170 | Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT02134067 | Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00262990 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneal neoplasm | Doxorubicin (NPC261012) | NP level |
NCT01454102 | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02596971 | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02047500 | Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04213898 | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00005087 | Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT01309789 | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | anaplastic large cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01075464 | A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | cancer | Paclitaxel (NPC208553) | NP level |
NCT00180908 | Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children | osteosarcoma | Doxorubicin (NPC261012) | NP level |
NCT02092363 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00811993 | A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00028938 | Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00111904 | Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01137994 | A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00004097 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00287937 | Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00450801 | R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00083057 | Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00001272 | A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00974584 | A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00886028 | Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma | malignant pleural mesothelioma | Doxorubicin (NPC261012) | NP level |
NCT01702129 | Anti-EGFR Immunoliposomes in Solid Tumors | neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00003215 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02051751 | Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01372202 | CHFR Methylation Status Esophageal Cancer Study | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00004055 | Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00054548 | Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00226590 | Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01653912 | Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02413320 | Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer | triple-negative breast cancer | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT01100931 | A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00225173 | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02279134 | Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03437070 | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
NCT00777673 | Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01186328 | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00809133 | Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03595059 | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01938846 | BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03116152 | Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04806945 | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT01688700 | Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00462423 | Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00006049 | ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00131027 | High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00815308 | Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT03766607 | Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00680940 | A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01404936 | Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02229058 | Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT04647344 | A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03179904 | FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03650933 | A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04996160 | Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT04683315 | PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00251472 | A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00998192 | A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung | squamous cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00276796 | Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00728845 | Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03317457 | Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03003520 | A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04083963 | Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00003377 | Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT03677141 | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
NCT00313768 | Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04231448 | Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04072263 | Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00735696 | A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00893516 | CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04257448 | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00465907 | Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02903004 | Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients | ovarian neoplasm | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT00276588 | Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00295893 | Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04336098 | Study of SRF617 in Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04835896 | Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02158520 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | cutaneous melanoma;metastatic melanoma | Paclitaxel (NPC208553) | NP level |
NCT00645177 | Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02890511 | A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00084448 | Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00951665 | A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01705483 | A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001) | cancer | Paclitaxel (NPC208553) | NP level |
NCT00004859 | Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04764227 | Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00919880 | Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03618550 | Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00004067 | Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT05179239 | A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT04808687 | Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer | pancreatic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03887442 | Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT02215447 | A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas | neuroendocrine carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02312804 | Ph Ib/BGJ398/Cervix and Other Solid Tumors | cervical carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03585062 | Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02677597 | Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03292822 | Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01730222 | A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00211185 | A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00918203 | A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03117751 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT02426281 | Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00006248 | S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00600340 | 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02448329 | Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03571308 | A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00004160 | Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00038558 | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00070629 | CPG 7909 Injection in Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04182724 | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00096226 | Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04308837 | A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02486601 | NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma | stomach neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00005800 | Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01461915 | Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01084083 | Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00370552 | A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02358161 | Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04973904 | Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT03994107 | Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04258657 | Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02243007 | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT02155088 | BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02827201 | FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00046423 | A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies | metastasis;neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00062179 | Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00003998 | Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02617485 | MabionCD20® Compared to MabThera® in Lymphoma Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00052468 | Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00483782 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02890602 | Erythropoietin for Management of Anemia Caused by Chemotherapy | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03524898 | NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma | soft tissue sarcoma | Paclitaxel (NPC208553) | NP level |
NCT00816634 | Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00856492 | S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01358877 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01063517 | Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00209222 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03975205 | To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames | leukemia;lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04910126 | Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT04341883 | Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00507962 | Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement | cancer | Doxorubicin (NPC261012) | NP level |
NCT00284752 | Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT02514031 | ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04551950 | Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT01547741 | Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03145558 | TATE Versus TACE in Intermediate Stage HCC | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT02317991 | Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00004916 | Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00231075 | Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients | inflammatory breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00522834 | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00574587 | Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT05025033 | Chemotherapy Combined With Apatinib and PD-1 Antibody | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01165216 | Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00060346 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02162719 | Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004) | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04888403 | Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02732938 | Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT04608409 | Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00278109 | Partial Breast Irradiation With Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00073723 | Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01637532 | Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT01992653 | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00028587 | PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04879368 | RegoNivo vs Standard of Care Chemotherapy in AGOC | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT01555853 | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | Hodgkins lymphoma;non-Hodgkins lymphoma | Paclitaxel (NPC208553) | NP level |
NCT05456022 | Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line | mouth neoplasm | Doxorubicin (NPC261012) | NP level |
NCT01087424 | Mini-CHOP and Rituximab in Patients Aged Over 80 Years | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02883062 | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00578864 | Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
NCT00003853 | 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00060385 | Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00051311 | Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers | hematopoietic and lymphoid cell neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00088088 | STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00062010 | Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00140140 | A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02406092 | Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00459121 | Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00136539 | Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00493025 | Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00049257 | Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT03804866 | NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT02501902 | Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT04188860 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy | cervical carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05233696 | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01548924 | Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01594099 | Concurrent Chemoradiotherapy for Cervical Cancer in Elderly Women | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00072007 | Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL | leukemia | Doxorubicin (NPC261012) | NP level |
NCT00001384 | A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01293630 | A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00123929 | Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03912415 | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA) | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00034190 | Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma | colorectal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00971945 | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03574324 | TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02427620 | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02054559 | R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | endometrioid carcinoma;undifferentiated carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05213312 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02251951 | Study of Afuresertib Combined With Paclitaxel in Gastric Cancer | cancer | Paclitaxel (NPC208553) | NP level |
NCT01459887 | Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04241276 | Phase IIb Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02372409 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | anaplastic astrocytoma;glioblastoma multiforme;oligoastrocytoma;oligodendroglioma;optic nerve glioblastoma;pilocytic astrocytoma | Doxorubicin (NPC261012) | NP level |
NCT02412722 | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT02570893 | A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT04263584 | Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03810872 | An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00303108 | Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | thyroid cancer | Paclitaxel (NPC208553) | NP level |
NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT05319639 | Phase I Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00887536 | A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00291850 | Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03502343 | Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02790580 | Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00002826 | Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00194753 | Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT01885013 | Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients | breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT02261805 | A Phase I/II Study of Ganetespib in Combination With Doxorubicin | small cell lung carcinoma | Doxorubicin (NPC261012) | NP level |
NCT02711137 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04877275 | ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT04799639 | Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00889382 | Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00198432 | Chemoradiotherapy of NSCLC Stage IIIB | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04711161 | First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03935256 | Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT03805399 | FUSCC Refractory TNBC Umbrella (FUTURE) | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00050960 | Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01889069 | A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02283372 | Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01116635 | Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00003313 | Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT04481009 | A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00401674 | MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00236899 | Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02138383 | Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01967043 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03330106 | A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01486602 | Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00563953 | Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00023907 | Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02187991 | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00005838 | Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery | lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03575520 | Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02414685 | First Line TIP in Poor Prognosis TGCTs. | germ cell tumor | Paclitaxel (NPC208553) | NP level |
NCT01647828 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01858883 | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02794571 | Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02362165 | CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT04859465 | Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma | angiosarcoma | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT00057382 | T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00112294 | Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05081609 | A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | cancer | Paclitaxel (NPC208553) | NP level |
NCT02993731 | A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01238133 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03527628 | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00971867 | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT02419495 | Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies | cutaneous melanoma;metastatic melanoma;non-small cell lung carcinoma;renal cell carcinoma;breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00903942 | Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02382406 | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03409198 | Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04046575 | Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02298283 | Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00280787 | Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05322720 | HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02595554 | Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer | cervical carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00295789 | Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3) | cervical adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00151034 | Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | urogenital neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00055887 | Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02270814 | Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03699449 | An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT01925612 | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02881125 | Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma | small cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01684878 | ICON8: Weekly Chemotherapy in Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00970385 | Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01481194 | ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00691912 | Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00003449 | Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00671658 | Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00002557 | Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03512834 | Paclitaxel-Avelumab for Angiosarcoma | angiosarcoma | Paclitaxel (NPC208553) | NP level |
NCT02783599 | A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT02734771 | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01039844 | Study of Weekly LOC-paclitaxel Injection for Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00087178 | Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01090128 | Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03407144 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03786783 | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | ganglioneuroblastoma;neuroblastoma | Doxorubicin (NPC261012) | NP level |
NCT01136031 | Paclitaxel and Irinotecan in Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01402271 | A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02855788 | Metronomic Chemotherapy in Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01696032 | Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00003092 | Paclitaxel in Treating Older Patients With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00478361 | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | urethra cancer;urinary bladder carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04286711 | Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00003165 | Doxorubicin in Treating Women With Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00063999 | Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | uterine neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00403130 | Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00193115 | Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00672295 | PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT01964391 | A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00055133 | A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis | rheumatoid arthritis | Paclitaxel (NPC208553) | NP level |
NCT00691236 | Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma | osteosarcoma | Doxorubicin (NPC261012) | NP level |
NCT02494713 | Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | prostate cancer | Doxorubicin (NPC261012) | NP level |
NCT00003644 | Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00448266 | Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00959387 | Induction Chemotherapy for Advanced Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT04835870 | Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00915005 | Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003086 | Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04176952 | PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01126216 | Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00102609 | A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00635050 | Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02670317 | Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00629278 | Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05344742 | A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01507428 | Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02350517 | Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00129376 | Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00512096 | Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis | penile cancer | Paclitaxel (NPC208553) | NP level |
NCT01154920 | Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05171530 | Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT03776812 | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Fallopian Tube Carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02389751 | Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003881 | Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00404235 | Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | cutaneous melanoma | Paclitaxel (NPC208553) | NP level |
NCT01110603 | A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) | cancer | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT02395705 | Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma | neoplasm of esophagus | Paclitaxel (NPC208553) | NP level |
NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00465673 | Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01325441 | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT03957590 | Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02630823 | MK-3475 Immunotherapy in Endometrial Carcinoma | endometrial carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01515306 | A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04267549 | Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Unresectable Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00025480 | Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00323583 | Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02476955 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00003317 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04656262 | Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00024401 | DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer | colorectal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02705196 | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00165087 | Treatment of Childhood Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT01784120 | A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04643405 | APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01324180 | Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT01329627 | Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00369070 | A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02607202 | A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP) | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | Fallopian Tube Carcinoma;Uterine Carcinosarcoma | Paclitaxel (NPC208553) | NP level |
NCT04358341 | Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer | gastric cancer | Doxorubicin (NPC261012) | NP level |
NCT03329248 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00373620 | A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT04592861 | Carbon Ion RT for Locally Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05190445 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02467907 | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT04038489 | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01705691 | Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04278092 | Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03756818 | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | ovarian carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01755845 | Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT01934634 | Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02545010 | Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00305084 | Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors | cancer | Doxorubicin (NPC261012) | NP level |
NCT00609765 | Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors | pancreatic carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01796197 | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04541108 | Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00268970 | Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04282070 | SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05322499 | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02125513 | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00009828 | Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03807999 | Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer | pancreatic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00002814 | Combination Chemotherapy for Patients With Brain Cancer | Central Nervous System Neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02861222 | Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma | malignant glioma | Doxorubicin (NPC261012) | NP level |
NCT02622074 | Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03161132 | Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT04081389 | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | breast carcinoma in situ | Paclitaxel (NPC208553) | NP level |
NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | angiosarcoma;triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01192165 | Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | cancer | Paclitaxel (NPC208553) | NP level |
NCT01394354 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT01498588 | Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer | thyroid cancer | Paclitaxel (NPC208553) | NP level |
NCT03579784 | Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00148681 | Preoperative Herceptin and Navelbine for Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05497778 | A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02327169 | A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors | cancer | Paclitaxel (NPC208553) | NP level |
NCT00933426 | Lenalidomide and Paclitaxel in Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT01227941 | MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT03023124 | Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor | neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00004092 | Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00554164 | Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01288261 | Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00004265 | Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00795340 | Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00513695 | Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | inflammatory breast carcinoma;male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03719924 | Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01912625 | Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00499603 | Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00360360 | Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00004057 | Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT04426955 | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00807573 | Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00990860 | Study in Asia of the Combination of TACE With Sorafenib in HCC Patients | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT04731038 | Combination Therapy for First Line Treatment of Advanced Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00319839 | Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT01666444 | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | fallopian tube cancer;ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00944047 | Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01649947 | Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03723967 | FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01605526 | A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00008138 | S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT04996004 | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
NCT01779050 | Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05200312 | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01435018 | Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS | HIV-1 infection | Paclitaxel (NPC208553) | NP level |
NCT00003065 | Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT03467373 | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | neoplasm of mature B-cells;non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00912444 | Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01669239 | Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00288041 | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT01057342 | Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02483104 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00135499 | R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03600623 | Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04802980 | A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03635489 | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT00001499 | Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00669773 | Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00798252 | Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | cancer | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT00004179 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00147537 | Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02506842 | Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | anus cancer;hypopharyngeal carcinoma;verrucous carcinoma;laryngeal squamous cell carcinoma;malignant epithelial tumor of ovary;oropharyngeal carcinoma;esophageal cancer;gastric cancer;HIV infection;non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04804696 | Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03617432 | Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients | neoplasm | Doxorubicin (NPC261012) | NP level |
NCT05214976 | A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00934895 | Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00502411 | Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00790244 | A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03056833 | Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00336791 | Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04765228 | Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03057600 | Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00011999 | Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT01396655 | PET in Breast Cancer Receiving Neoadjuvant Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00733408 | Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02937272 | A Study of LY3200882 in Participants With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03278015 | Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02109341 | Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01412229 | Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT03872791 | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01667211 | Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00193310 | Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04729608 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03189446 | Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00556088 | LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00508625 | A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00017407 | Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03467178 | Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02889523 | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | diffuse large B-cell lymphoma;follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00561119 | Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05441254 | Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis:Single-arm, Prospective Clinical Study | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00102622 | Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00003064 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT03943901 | Split-Dose R-CHOP for Older Adults With DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02273713 | The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02715804 | A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00577993 | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04589234 | Saltikva for Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003111 | Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03003546 | Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial | chronic lymphocytic leukemia | Paclitaxel (NPC208553) | NP level |
NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer | breast ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03981796 | A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02419495 | Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies | renal cell carcinoma;cutaneous melanoma;metastatic melanoma;breast carcinoma;non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02451943 | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03952572 | Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01100372 | Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Doxorubicin (NPC261012) | NP level |
NCT00923936 | Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | Kaposi's sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00021060 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00183742 | Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) | carcinoma | Doxorubicin (NPC261012) | NP level |
NCT02472353 | Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00499083 | Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05201547 | Endometrial Cancer Patientes MMR Deficient Comparing Chimiotherapy vs Dostarlimab in First Line | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT04339738 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | angiosarcoma | Paclitaxel (NPC208553) | NP level |
NCT03126812 | Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00574587 | Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05290935 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial | cervical carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00479856 | Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01004991 | Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03884556 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00558636 | A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00265031 | HD12 for Advanced Stages | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03517137 | Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03462212 | Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2) | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT05017012 | A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18) | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00815945 | Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors | carcinosarcoma;leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
NCT03064126 | RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty | peripheral arterial disease | Paclitaxel (NPC208553) | NP level |
NCT00350948 | Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00005831 | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | urinary bladder carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00198354 | Stage I/II NSCLC Perioperative Chemotherapy | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00014222 | Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02033993 | Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen. | urogenital neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00859495 | Trimodal Lung-Sparing Treatment of Pleural Mesothelioma | mesothelioma | Doxorubicin (NPC261012) | NP level |
NCT00553358 | Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04460352 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00193206 | Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02810418 | Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | pancreatic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00002854 | High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer | cancer | Paclitaxel (NPC208553) | NP level |
NCT00208936 | Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus | gastrointestinal disease | Paclitaxel (NPC208553) | NP level |
NCT00003214 | Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02262897 | The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03490292 | Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00004202 | Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00003035 | Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02994251 | A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma | cholangiocarcinoma | Doxorubicin (NPC261012) | NP level |
NCT04572542 | Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00717340 | A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02607332 | Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib | gastrointestinal stromal tumor | Paclitaxel (NPC208553) | NP level |
NCT03866993 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | squamous cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03553238 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT04151277 | PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00988195 | Study of Pegylated Human Recombinant Arginase for Liver Cancer | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00049790 | Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04175912 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | hepatocellular carcinoma;intrahepatic cholangiocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT02715531 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03579771 | Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer | intrahepatic cholangiocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03188198 | Risk Adapted Therapy in Diffuse Large B Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00193193 | Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT05371093 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00113516 | A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01364012 | A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04498793 | Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03933319 | Phase Ⅱ Study of Pegylated Liposomal Doxorubicin(PLD)Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04475016 | TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | penile cancer | Paclitaxel (NPC208553) | NP level |
NCT00724386 | Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01405235 | Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00136435 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00980954 | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT04016142 | Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT02661503 | HD21 for Advanced Stages | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003907 | Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver | liver cancer | Doxorubicin (NPC261012) | NP level |
NCT05262335 | Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00089297 | Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT01994031 | Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00378313 | A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05177796 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00002772 | S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01419548 | ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04807140 | Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003421 | Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003150 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00334763 | Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02566993 | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | small cell lung carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00005059 | Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04974996 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003378 | Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00003555 | Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00004126 | Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00004125 | Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00028990 | Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00084565 | Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT03322969 | Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX) | inflammatory breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02182245 | Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies | Genital neoplasm, female | Paclitaxel (NPC208553) | NP level |
NCT01139359 | Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00533585 | BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00628251 | Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
NCT04884906 | Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT04935359 | Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003614 | Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00042302 | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | brain neoplasm;glioblastoma multiforme | Paclitaxel (NPC208553) | NP level |
NCT00081042 | ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma | cutaneous melanoma | Paclitaxel (NPC208553) | NP level |
NCT00258960 | Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03026881 | A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02931890 | Multicentric Randomised Trial for Resectable Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT04209686 | Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01121406 | BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT03643276 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT03393507 | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03588039 | Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00373256 | Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00931918 | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01739218 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01258634 | A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response | osteosarcoma | Doxorubicin (NPC261012) | NP level |
NCT03412643 | Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01187199 | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | cancer | Paclitaxel (NPC208553) | NP level |
NCT01381211 | Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC) | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00004013 | Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00398086 | Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03018626 | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03915444 | Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT02581501 | Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03539328 | Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT02049905 | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00779129 | A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT02834975 | Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00654758 | A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00038142 | Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients | Ewing sarcoma | Doxorubicin (NPC261012) | NP level |
NCT04821284 | Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01696032 | SGI-110 in Combination With Carboplatin in Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00055601 | Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT01843829 | A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00854568 | Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00113438 | Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors | cancer | Paclitaxel (NPC208553) | NP level |
NCT00890656 | Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT02341456 | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00731861 | Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors | metastasis;carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00976911 | Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00255762 | Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00017303 | Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer | ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02461043 | Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00003327 | Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00027937 | Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00112489 | Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer | sarcoma | Paclitaxel (NPC208553) | NP level |
NCT00680758 | Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04887961 | Reprab Study: PLD + Trabectedin Rechallenge | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT01946074 | A Study of ABT-165 in Subjects With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02172846 | Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03542669 | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | ovarian carcinoma | Doxorubicin (NPC261012) | NP level |
NCT02272790 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00259675 | Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00002949 | Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis | vaginal cancer;cervical cancer;endometrial cancer;urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT04776525 | Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00088556 | Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03740165 | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00016913 | Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT05113251 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00956930 | Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery | liver cancer | Doxorubicin (NPC261012) | NP level |
NCT04332822 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04354961 | Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma (ARISE) | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01778803 | A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01251107 | Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00113399 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00146562 | Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00101101 | Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04056949 | Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03668730 | Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04225364 | Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01933061 | Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma | metastatic melanoma | Paclitaxel (NPC208553) | NP level |
NCT02020707 | Abraxane/Bevacizumab | peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT04251533 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03416153 | Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer | oropharynx cancer | Paclitaxel (NPC208553) | NP level |
NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00368875 | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00443677 | Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05446870 | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | ovarian carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01138046 | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01649856 | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00797472 | Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma | multiple myeloma | Paclitaxel (NPC208553) | NP level |
NCT02255110 | A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00217607 | Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery | sarcoma | Paclitaxel (NPC208553) | NP level |
NCT04492033 | A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | biliary tract cancer | Paclitaxel (NPC208553) | NP level |
NCT00622466 | Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00290498 | Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00819221 | AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours | neoplasm | Doxorubicin (NPC261012) | NP level |
NCT05007145 | PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02307227 | A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00024310 | Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00294762 | Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00004112 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003084 | Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT01319981 | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | leukemia | Doxorubicin (NPC261012) | NP level |
NCT01593020 | Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03818282 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03940196 | Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00039546 | Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00004093 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00003376 | Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | urethra cancer;urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT00001426 | A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05459129 | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01704690 | Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00991796 | CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ovarian serous cystadenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00006229 | Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00540514 | Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01010945 | Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00266799 | The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03005015 | Lenvatinib in Second Line Endometrial Carcinoma | endometrial neoplasm | Doxorubicin (NPC261012) | NP level |
NCT02822157 | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer | malignant epithelial tumor of ovary | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT03423979 | Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter | benign prostatic hyperplasia | Paclitaxel (NPC208553) | NP level |
NCT00268450 | Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT00454649 | Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00559845 | A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04929041 | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | lung adenocarcinoma;squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02733250 | Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00878254 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00256243 | Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00907348 | Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003088 | Combination Chemotherapy in Treating Patients With Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00022633 | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract | urethra cancer;urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT00607438 | A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02850419 | Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00426127 | Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer | pancreatic carcinoma | Doxorubicin (NPC261012) | NP level |
NCT02054884 | F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | Merkel cell skin cancer | Paclitaxel (NPC208553) | NP level |
NCT00455897 | CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03056833 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00331630 | Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03975270 | Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00518284 | Prevention of Restenosis Following Revascularization | peripheral vascular disease | Paclitaxel (NPC208553) | NP level |
NCT00365417 | Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00356681 | A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02951728 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01702714 | A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02597036 | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02453282 | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03725436 | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04561817 | To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00135135 | Therapy for Children With Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
NCT01711970 | SGI-110 in Combination With Carboplatin in Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03853044 | Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | angioimmunoblastic T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04908787 | PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00343083 | Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03059615 | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS | acute myeloid leukemia;myelodysplastic syndrome | Doxorubicin (NPC261012) | NP level |
NCT02551432 | Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04698941 | Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04025593 | Biomarker Guided Treatment in DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00002922 | Paclitaxel in Treating Patients With Advanced Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT03136055 | Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas | neuroendocrine carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00007904 | Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00003193 | Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00448591 | A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer. | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00322400 | Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01534585 | Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01969578 | Androgen Deprivation Therapy in Advanced Salivary Gland Cancer | salivary gland cancer | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT04694183 | The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT05449366 | Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma | malignant peritoneal mesothelioma | Paclitaxel (NPC208553) | NP level |
NCT02771743 | Response-based Treatment of High-risk Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
NCT01519804 | A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma | small cell lung carcinoma | Doxorubicin (NPC261012) | NP level |
NCT03393884 | Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT01083537 | Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00005021 | Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT04843098 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00789581 | A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02317874 | Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02367794 | A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003158 | S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00290732 | Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00687817 | Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05389423 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | Burkitts lymphoma;diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00337376 | A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers | cancer | Paclitaxel (NPC208553) | NP level |
NCT00688740 | Docetaxel in Node Positive Adjuvant Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04826679 | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00204646 | Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS) | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00189371 | Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum | anemia (phenotype);ovarian cancer;peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03932409 | Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00093756 | Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03257033 | Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01721746 | A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | metastatic melanoma | Paclitaxel (NPC208553) | NP level |
NCT01240655 | A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02043730 | Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer. | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00384826 | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma | bronchoalveolar adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01746238 | Bevacizumab/Doxorubicin/Radiation for Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT01617928 | A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00020007 | Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00079430 | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | ovarian serous cystadenocarcinoma;endometrioid carcinoma;fallopian tube cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00174356 | PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03240016 | Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer | urothelial carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00667251 | Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00891605 | Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04449549 | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00314678 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00542191 | Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT05097248 | Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04661007 | To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00006118 | Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT01090830 | Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00146562 | Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01321008 | Stage I/II Nasal NK Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00344552 | Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00110019 | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | cutaneous melanoma | Paclitaxel (NPC208553) | NP level |
NCT02405910 | Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00864253 | A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT05357846 | PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003013 | Chemotherapy Plus Surgery in Treating Women With Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01659099 | GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00004010 | Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02133612 | Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT01882816 | Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer | thyroid cancer | Doxorubicin (NPC261012) | NP level |
NCT00462397 | Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT01008150 | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00979082 | Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | peripheral neuropathy | Paclitaxel (NPC208553) | NP level |
NCT03635489 | Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00006110 | Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00702572 | Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02689427 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00737243 | Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site | carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02124707 | Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00094497 | Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) | carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01332656 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00003281 | Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00003691 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT04203641 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | pancreatic carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00796120 | An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00506779 | Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma | uterine cancer | Paclitaxel (NPC208553) | NP level |
NCT04895358 | 9-ING-41 in Patients With Advanced Cancers | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00346229 | Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01966133 | TACE as an Adjuvant Therapy After Hepatectomy for HCC | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT04685616 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | bronchoalveolar adenocarcinoma;large cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | Castleman disease;diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03167164 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | Merkel cell skin cancer | Paclitaxel (NPC208553) | NP level |
NCT03181100 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | thyroid carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00210379 | Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05013697 | TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer. | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00004054 | Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00312650 | Doxil and Gemcitabine in Recurrent Ovarian Cancer | ovarian carcinoma | Doxorubicin (NPC261012) | NP level |
NCT03201471 | Chidamide With R-CHOP Regimen for DLBCL Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01953445 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00574236 | Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02741856 | Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT04227990 | Plinabulin iv Solution in Prevention of TAC Induced Neutropenia | neutropenia | Doxorubicin (NPC261012) | NP level |
NCT00929162 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00513786 | Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT02259621 | Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02131480 | Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | ovarian carcinoma;breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01196741 | Neoadjuvant Therapy for Ovarian Cancer | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01204996 | A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors | cancer | Paclitaxel (NPC208553) | NP level |
NCT00666692 | A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01204801 | Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00006018 | Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01104298 | Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00642759 | Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00191854 | Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00591851 | Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00596830 | Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | large cell lung carcinoma;squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00152477 | A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003294 | Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer | leukemia;lymphoma | Paclitaxel (NPC208553) | NP level |
NCT02101021 | Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT02630199 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | cancer | Paclitaxel (NPC208553) | NP level |
NCT01820325 | Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT01857934 | Therapy for Children With Advanced Stage Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
NCT02483247 | A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT01220154 | Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel Bevacizumab for Primary Ovarian | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00426556 | Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00919984 | Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02199418 | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer | inflammatory breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00936702 | Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary | carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01070862 | Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies. | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00063258 | Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00008021 | Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00281658 | ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00003235 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03636308 | Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00006378 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04540692 | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | endometrioid carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02072317 | Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00108953 | A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00107341 | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00003159 | Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00873119 | Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary | carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00337532 | A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT04980222 | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00585689 | Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT02121990 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT02792491 | Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03398655 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT05290090 | ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00535119 | Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer | Hereditary breast and ovarian cancer syndrome | Paclitaxel (NPC208553) | NP level |
NCT02684227 | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | uterine neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00803556 | Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00662597 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04261465 | Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00393068 | Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02292979 | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00490711 | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00009802 | Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02449278 | The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03344172 | Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003299 | Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02730416 | Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT04480099 | Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01455532 | A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors | neoplasm | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT01485848 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02440425 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03281369 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | esophageal carcinoma;gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT04047862 | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00264953 | HD11 for Intermediate Stages | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00217425 | Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01146795 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT05410847 | Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02366949 | A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT00003927 | Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02279732 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00484341 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT05052931 | Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00268853 | A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02428751 | R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02611700 | Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00613457 | Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | leukemia | Doxorubicin (NPC261012) | NP level |
NCT00301730 | Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05189184 | Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01655693 | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT02713386 | Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | T-cell acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT02039791 | Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT03989310 | An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00503906 | Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03595592 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00657878 | Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval | ovarian cancer | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT01566435 | Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer | upper aerodigestive tract neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00083226 | Doxorubicin and Bortezomib in Treating Patients With Liver Cancer | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01279291 | Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer | Fallopian Tube Carcinoma;peritoneal neoplasm | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT00662311 | Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00796991 | Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00004089 | Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT02364999 | A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03425656 | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02459457 | A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02157870 | Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00265018 | HD10 for Early Stages | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04211012 | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | urothelial carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04902261 | Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003992 | Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04821765 | Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT01641783 | Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03143491 | Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) | cervical intraepithelial neoplasia | Paclitaxel (NPC208553) | NP level |
NCT03797443 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04155671 | POF Versus FOLFOX Plus IP Paclitaxel in AGC | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01525602 | Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT01057264 | HAI Abraxane With Gemcitabine and Bevacizumab | cancer | Paclitaxel (NPC208553) | NP level |
NCT03503786 | Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00070278 | Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05189483 | Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. | soft tissue sarcoma | Paclitaxel (NPC208553) | NP level |
NCT03997123 | A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03704077 | An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00280150 | Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00446030 | Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT01496742 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02027428 | Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00600977 | Liposomal Anthracyclin in the Treatment of Elderly ALL | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT03885219 | Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01131364 | Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | acute leukemia of ambiguous lineage;acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT01040871 | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04138719 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02340117 | Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01548573 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT03830385 | Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01541332 | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00639522 | Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma | gastric carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03943043 | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | cholangiocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT02004093 | EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT04337632 | NUVOLA TRIAL Open-label Multicentre Study | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03030287 | A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | Fallopian Tube Carcinoma;ovarian carcinoma;peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00894569 | Paclitaxel/Carboplatin With or Without Cetuximab in CUP | carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01024062 | Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01959490 | Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01219777 | TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03564691 | Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02725268 | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer | endometrial neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00277043 | A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes | allergic disease | Paclitaxel (NPC208553) | NP level |
NCT00038545 | A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Paclitaxel (NPC208553) | NP level |
NCT05386524 | Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00734877 | UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT01756170 | Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT03294577 | Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia | neutropenia | Doxorubicin (NPC261012) | NP level |
NCT05189197 | A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01451515 | NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01118026 | Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04790903 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01471132 | Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT04348032 | Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00085358 | Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) | ovarian serous cystadenocarcinoma;endometrioid carcinoma;fallopian tube cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT04603846 | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | urothelial carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00531687 | Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer | testicular carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00041132 | S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00016406 | S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00005647 | SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT02048943 | Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00004011 | S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00825149 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01004978 | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT02625623 | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01220128 | Treatment With Pazopanib for Neoadjuvant Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT04850235 | Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00513383 | Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02414568 | Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003387 | Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00801281 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | chronic lymphocytic leukemia;follicular lymphoma;lymphoplasmacytic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01963325 | S-1 in Combination With Abraxane in Treating Cholangiocarcinoma | cholangiocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT02644863 | Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04528680 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma | gliosarcoma | Paclitaxel (NPC208553) | NP level |
NCT00226915 | Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01491204 | Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04762901 | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01969955 | Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer | squamous cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03639246 | Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01244789 | Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT02488564 | A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00061646 | Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00002972 | Paclitaxel in Treating Patients With Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00353717 | Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | endometrioid carcinoma;Fallopian Tube Carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00626561 | Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT05351346 | Genotype-guided Treatment in DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003440 | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03430843 | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00100139 | Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03639246 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00686114 | Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT04005170 | Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT03020030 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT05192798 | Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01862328 | Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01107665 | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT01024101 | Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00725231 | Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP | angioimmunoblastic T-cell lymphoma;extranodal nasal NK/T cell lymphoma;unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003389 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00318136 | A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00191672 | A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00849472 | Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03485118 | RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05088057 | Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02710734 | Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) | urinary bladder carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00841945 | Treatment of Aggressive Localized Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03571321 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT02858206 | Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00401817 | Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04159818 | Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04001829 | Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01527864 | Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00450385 | Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003206 | Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT04568200 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00001569 | Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis | peritoneal neoplasm;carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01113957 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT02098343 | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT05481645 | Efficacy and Safety of TQB2450 Combined With Chemotherapy ± Anlotinib for Advanced Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00493870 | TAC Versus TC for Adjuvant Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02471820 | Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT03384654 | A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT02911350 | Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT04943653 | Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis | stomach neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00840450 | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00032032 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04148885 | A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00850577 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05203913 | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer | urinary bladder carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03556839 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix | cervical carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00772798 | Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00193362 | Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01009970 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01246063 | Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT03503604 | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02448537 | A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03367871 | Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00287989 | Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00005051 | Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT04077983 | Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma | cholangiocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01491217 | A Study of Oraxol® in Gastric Cancer Patients | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00011986 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00003612 | Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01490047 | Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02142738 | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03340376 | Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer | cervical cancer | Doxorubicin (NPC261012) | NP level |
NCT01015222 | Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT00049595 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00591851 | Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02632305 | A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer | biliary tract cancer | Paclitaxel (NPC208553) | NP level |
NCT00788931 | A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02036164 | Adjuvant Chemotherapy for Locally Advanced Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT02474173 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00109837 | S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | leukemia | Doxorubicin (NPC261012) | NP level |
NCT00586846 | Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma | osteosarcoma | Doxorubicin (NPC261012) | NP level |
NCT00040794 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00575406 | Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03274492 | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00006012 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02958163 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR) | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT04566887 | Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03167177 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | melanoma | Paclitaxel (NPC208553) | NP level |
NCT03762564 | Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00111787 | Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00590785 | Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00084214 | STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00006484 | Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04015661 | Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03742986 | Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00954642 | A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | cancer | Paclitaxel (NPC208553) | NP level |
NCT02487277 | PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma | adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00005849 | Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00392392 | Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02012192 | A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03991884 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00966914 | Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00369681 | Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00660842 | Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00723125 | Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00245154 | Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01969032 | Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03603756 | SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01239732 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01327521 | Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT03283696 | A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT05318794 | Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer | gastric cancer | Doxorubicin (NPC261012) | NP level |
NCT00984464 | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | metastatic melanoma | Paclitaxel (NPC208553) | NP level |
NCT00025688 | Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00003541 | Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00358163 | Trial of PTK787/ZK 222584 Plus Paclitaxel | cancer | Paclitaxel (NPC208553) | NP level |
NCT01646762 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma | multiple myeloma | Paclitaxel (NPC208553) | NP level |
NCT05174156 | Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT03600090 | Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00691912 | Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00524303 | EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00136175 | Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT01570582 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01636622 | Study of Vemurafenib, Carboplatin, and Paclitaxel | cancer | Paclitaxel (NPC208553) | NP level |
NCT04338399 | The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00004863 | Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01235897 | MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT00003732 | Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT03776812 | A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00154804 | CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02429622 | Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00524810 | Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00181701 | Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | ovarian carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00001498 | A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00093119 | Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT03159897 | FIL Study on ABVD DD-DI as Upfront Therapy in HL. | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02096588 | Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03126812 | Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT00610792 | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00026208 | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00189137 | Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT05092373 | Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax | renal cell carcinoma;hepatocellular carcinoma;endometrial carcinoma;Fallopian Tube Carcinoma;ovarian carcinoma;breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03042819 | Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00009997 | Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02769832 | Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02389985 | Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01854255 | Intraperitoneal Aerosol Chemotherapy in Gastric Cancer | gastric cancer | Doxorubicin (NPC261012) | NP level |
NCT00191256 | Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00085839 | Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03712202 | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04705519 | Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma | neuroendocrine carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01641939 | A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00006459 | Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01166542 | Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00480831 | A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03197584 | Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00997906 | Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT03603184 | Atezolizumab Trial in Endometrial Cancer - AtTEnd | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00174434 | Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00434252 | A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT01783197 | Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02723331 | Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00193596 | Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05051891 | A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01000285 | EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma | T-cell acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00334321 | Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT00721747 | Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03410784 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00499525 | Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00005065 | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00945191 | A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT04447092 | Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma | oral squamous cell carcinoma;oropharynx squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04149015 | Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00722293 | A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT01015339 | Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00317200 | A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02432365 | Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00187161 | Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT04158635 | Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00034541 | Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04581265 | Nab-PTX, Ifosfamide and Cisplatin in the Treatment of Pediatric Extracranial Germ Cell Tumor. | germ cell tumor | Paclitaxel (NPC208553) | NP level |
NCT00512980 | PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00422682 | A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00001387 | Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00550537 | Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00570531 | Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT04164238 | Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients | head and neck squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003558 | Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin | carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05018520 | The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00618826 | A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00042809 | Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04674956 | A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00467012 | Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01492881 | Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT03649321 | Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01026116 | Treatment With Pazopanib for Neoadjuvant Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00139633 | Selective Dose Escalation for Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT01301716 | A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors | cancer | Paclitaxel (NPC208553) | NP level |
NCT00903656 | Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00753038 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma | squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01253681 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | fallopian tube cancer | Paclitaxel (NPC208553) | NP level |
NCT00786110 | Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients | adrenal cortex carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00388076 | A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00730925 | Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02412670 | Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer | urothelial carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00581360 | Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck | adenoid cystic carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01008150 | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04664972 | The TP Regimen in the Treatment of Early Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02718417 | Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | endometrioid carcinoma;undifferentiated carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00319865 | PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00003696 | Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03941093 | Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00471965 | Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT03737643 | An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00429299 | Wkly Taxol x 12 | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00005078 | Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00003592 | Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT02322281 | TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00002953 | Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00551733 | Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma | pancreatic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02761694 | Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase | cancer | Paclitaxel (NPC208553) | NP level |
NCT01227408 | Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00024414 | DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00758732 | Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00001383 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | renal cell carcinoma;lymphoma;ovarian cancer;breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02303977 | Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy | lung adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03467178 | Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00085501 | S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02732015 | Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00002318 | A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma | Kaposi's sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00850512 | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04814485 | Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00666991 | Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers | peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00343291 | A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03154294 | Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03553537 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01055028 | Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma | angiosarcoma | Paclitaxel (NPC208553) | NP level |
NCT04679064 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00861120 | Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT02623972 | A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | inflammatory breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01858207 | Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00473889 | A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03678883 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT05390710 | PhI to Solid Tumors and PhII to Locally Advanced or mTNBC | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00045630 | S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium | urethra cancer;urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT04584112 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT00948675 | Study of Participants With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03246074 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02449655 | Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT04383743 | Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer | urinary bladder carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01326767 | Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02979522 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00611962 | Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin | germ cell tumor | Paclitaxel (NPC208553) | NP level |
NCT00455533 | Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00041210 | Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03023358 | Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00011921 | Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00034151 | Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02311907 | Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | neuropathy;pain | Paclitaxel (NPC208553) | NP level |
NCT00021320 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT03949634 | Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD) | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00006721 | S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00186888 | Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma | retinoblastoma | Doxorubicin (NPC261012) | NP level |
NCT04753879 | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00046527 | Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer | metastasis;breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00002519 | Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT05185869 | SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02911142 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | B-cell neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00911183 | Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01199055 | CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00021372 | Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT00016874 | 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00017160 | Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02226757 | Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03777462 | Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02633137 | Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02033538 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00822120 | S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00866749 | Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma | lymphoid leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04012827 | Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT04729387 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02756013 | Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0 | urogenital neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05238064 | Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL | mature T-cell and NK-cell non-Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01236716 | Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00366106 | Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT05498259 | Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02659930 | Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma | Kaposi's sarcoma | Doxorubicin (NPC261012) | NP level |
NCT02121990 | Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00832819 | E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00976677 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01210768 | A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00960297 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04213937 | Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer | small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04077905 | Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis. | hemophagocytic syndrome | Doxorubicin (NPC261012) | NP level |
NCT02654119 | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00944801 | Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | glioblastoma multiforme | Doxorubicin (NPC261012) | NP level |
NCT03018080 | Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05207514 | Compare the Efficacy and the Safety of Doxorubicin and Cyclophosphamide Followed by Taxotere Versus Doxorubicin and Cyclophosphamide Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01672671 | BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00003251 | Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00394251 | Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01376310 | GSK1120212 Rollover Study | cancer | Paclitaxel (NPC208553) | NP level |
NCT00653952 | CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04104672 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02210559 | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00191646 | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | Fallopian Tube Carcinoma;ovarian neoplasm;peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01836432 | Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03641183 | Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00010257 | Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma | Thymic Carcinoma;Thymoma | Paclitaxel (NPC208553) | NP level |
NCT01678664 | Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors | neuroendocrine neoplasm | Doxorubicin (NPC261012) | NP level |
NCT04535713 | GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01719835 | CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study | anaplastic large cell lymphoma;angioimmunoblastic T-cell lymphoma;unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02252796 | Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00784537 | High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02449252 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00580333 | Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03487016 | First-line Therapy in Metastatic PDAC | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03004287 | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00201318 | A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04199026 | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT02107937 | Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma | malignant epithelial tumor of ovary | Paclitaxel (NPC208553) | NP level |
NCT05467670 | Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT04296175 | Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00311636 | Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00024388 | Chemotherapy in Treating Patients With Metastatic Kidney Cancer | kidney cancer | Paclitaxel (NPC208553) | NP level |
NCT03698227 | OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00206518 | Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00054210 | Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00256243 | Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00614484 | Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00964626 | Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00054028 | Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02391662 | Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00486668 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01006252 | A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00849472 | A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948) | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT04483076 | Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00184002 | Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04876313 | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) | urinary bladder carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00610714 | AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01702844 | Single Arm on the Tolerability of Weekly Nab-paclitaxel | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00715208 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02421588 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT02739529 | Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer | female reproductive system neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04085276 | Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02606305 | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | fallopian tube cancer;ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT02559674 | QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03604965 | GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00517621 | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | fallopian tube cancer;ovarian cancer;peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02916511 | Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02063022 | Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma | Ewing sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03273595 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01487226 | Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT01834235 | QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04293393 | Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00028873 | R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00470301 | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | male breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00440726 | Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT01763645 | A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00075712 | Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT05422794 | Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02301143 | Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC) | pancreatic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00003298 | Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT01993810 | Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00668616 | Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00833261 | Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT01851733 | MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme | glioblastoma multiforme | Doxorubicin (NPC261012) | NP level |
NCT01263145 | MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01527422 | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02319889 | Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00004174 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03415802 | Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00679029 | Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02751918 | Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
NCT01646034 | High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03515200 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00022217 | Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00762034 | A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003133 | Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT00136539 | Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01821859 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00629499 | Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04858009 | Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00879359 | Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer | endometrial carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00572169 | UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT02735239 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02598687 | Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer. | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00003589 | Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03520790 | Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01379989 | INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00702975 | Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02326025 | A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT03726879 | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02639650 | Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor | gestational trophoblastic neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01386385 | Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | squamous cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01390584 | Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02499367 | Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01276496 | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | male breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00005048 | Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | prostate cancer | Paclitaxel (NPC208553) | NP level |
NCT00960960 | A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00176241 | Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00453167 | Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT04650984 | A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00331422 | Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT03410030 | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT01591135 | A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02013453 | A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00003130 | Paclitaxel in Treating Women With Recurrent Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00004934 | Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02766582 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00016406 | S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT05328336 | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT02103062 | Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer | colorectal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00808639 | Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
NCT00209612 | Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC. | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT04590625 | Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00944047 | Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02044601 | Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00254891 | Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00005867 | Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00009776 | Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma | lymphoma | Paclitaxel (NPC208553) | NP level |
NCT01215344 | First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT01712919 | Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) | nasopharyngeal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00231582 | High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II | testicular neoplasm | Paclitaxel (NPC208553) | NP level |
NCT05042128 | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03004833 | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00005032 | Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT05158062 | Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer | ovarian carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01820858 | The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma | endometrial neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00063401 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Fallopian Tube Carcinoma;ovarian cancer;peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00003089 | Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03825328 | A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC ) | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01770171 | Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT02285062 | Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003413 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02163291 | Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer | gastric carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02978495 | Neoadjuvant Carboplatin in Triple Negative Breast Cancer | Hereditary breast and ovarian cancer syndrome | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT02422563 | NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00949325 | Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00250874 | Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03335241 | Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00091377 | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02328105 | LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT03399747 | Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00006004 | Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00002837 | High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00347412 | Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00404404 | ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00336791 | Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05257993 | Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT05241249 | Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01746173 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | T-cell non-Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00707707 | Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01924533 | Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00052936 | Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01415336 | AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00031577 | Paclitaxel Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma | Central Nervous System Neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03036488 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04247126 | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | small cell lung carcinoma;pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00484601 | Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00616031 | Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00482391 | Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00577629 | Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01060904 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00730353 | Sutent + Taxol for Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT04374630 | Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00920153 | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02717091 | Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03990103 | S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT04723875 | Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline | cervical adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT05428670 | The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00068393 | Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma | renal cell carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00912639 | A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00169156 | A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma | angioimmunoblastic T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05234684 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00494780 | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00034177 | Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium | urogenital neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00530101 | The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01107626 | Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01868022 | Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02315196 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT03693612 | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00818090 | Paclitaxel and Cisplatin for Thymic Neoplasm | Thymic Carcinoma;Thymoma | Paclitaxel (NPC208553) | NP level |
NCT04529772 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00252798 | ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00566540 | Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT01970722 | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | Fallopian Tube Carcinoma;ovarian carcinoma;uterine neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01176799 | Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02106546 | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02881086 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01581476 | Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial | type 1 diabetes mellitus | Paclitaxel (NPC208553) | NP level |
NCT03197571 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | urothelial carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00002628 | Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | prostate adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT03574779 | A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer | ovarian neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01204749 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00686322 | Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03901118 | Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00866528 | Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02215876 | Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003352 | Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT03517176 | CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03601897 | A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04129996 | A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05218499 | Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | dedifferentiated liposarcoma | Doxorubicin (NPC261012) | NP level |
NCT00915603 | Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00869232 | UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00795899 | Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO) | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02892123 | Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | cancer | Paclitaxel (NPC208553) | NP level |
NCT00087217 | 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT04908787 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00434031 | CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02039674 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003385 | Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT05020860 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01225302 | A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00038610 | Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | leukemia | Doxorubicin (NPC261012) | NP level |
NCT01310244 | MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00006257 | SU5416 and Paclitaxel in Treating Patients With Advanced Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT01113476 | Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies | cancer | Paclitaxel (NPC208553) | NP level |
NCT00768131 | A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01264328 | Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | fallopian tube cancer | Doxorubicin (NPC261012);Paclitaxel (NPC208553) | NP level |
NCT00300885 | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01009515 | Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT00930930 | Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | multiple myeloma | Paclitaxel (NPC208553) | NP level |
NCT00324467 | Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | neoplasm of mature B-cells;non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00003050 | Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01839097 | Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01196234 | Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03435289 | A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02107378 | Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma | ovarian carcinoma | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT02560038 | Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer | bladder tumor | Paclitaxel (NPC208553) | NP level |
NCT00878800 | A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT02247869 | Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) | triple-negative breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00669877 | Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma | Burkitts lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00006454 | Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT02181634 | Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma | cholangiocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT05346107 | PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00691054 | Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04221035 | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | neuroblastoma | Doxorubicin (NPC261012) | NP level |
NCT04844385 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02615730 | PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT04510064 | PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00025389 | Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01297452 | BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02050009 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT02193633 | Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel | cancer | Paclitaxel (NPC208553) | NP level |
NCT00030381 | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | primary systemic amyloidosis | Doxorubicin (NPC261012) | NP level |
NCT00755261 | Phase II Study of Doxorubicin and Avastin® in Sarcoma. | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT04172259 | ACH-TH vs EC-TH as Neoadjuvant Therapy for HER2-positive EBC | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00069953 | Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT02762981 | Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00559845 | A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT03740165 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | peritoneal neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02192021 | Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) | Cutaneous T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT05319730 | A Study to Evaluate Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01497470 | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen | cancer | Paclitaxel (NPC208553) | NP level |
NCT00014573 | Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer | Central Nervous System Neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03977220 | Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT03946969 | Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05093920 | Role of DEB-TACE Versus c-TACE in Treatment of HCC | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00246571 | Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00002632 | Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | ovarian carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00584909 | A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus | uterine cancer | Paclitaxel (NPC208553) | NP level |
NCT03751761 | GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00193141 | Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT04024462 | A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT04660799 | A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00434226 | A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00520000 | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00043108 | Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00475670 | A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02506803 | Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer. | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05108870 | TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers | oropharynx squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03087864 | PDL-1 Targeting in Resectable Oesophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT03486314 | A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00004173 | Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00273507 | Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3 | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01632306 | A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04968106 | Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) | sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00392704 | Treatment of Head & Neck Cancer With Chemotherapy and Radiation | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT00003930 | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00002913 | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer | ovarian serous cystadenocarcinoma;endometrioid carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05448820 | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00002939 | Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03349281 | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT00024102 | Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00033696 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00461344 | Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer | breast ductal carcinoma in situ | Doxorubicin (NPC261012) | NP level |
NCT04180384 | A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03038100 | IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery | fallopian tube cancer;ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00662129 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02651727 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00077129 | Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer | kidney cancer | Paclitaxel (NPC208553) | NP level |
NCT01704287 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) | melanoma | Paclitaxel (NPC208553) | NP level |
NCT03537690 | FID-007 in Treating Participants With Advanced Solid Tumors | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00983424 | Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01009801 | Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer | liver cancer | Doxorubicin (NPC261012) | NP level |
NCT01493505 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | fallopian tube cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00107094 | Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00002888 | Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer | head and neck malignant neoplasia | Paclitaxel (NPC208553) | NP level |
NCT03690739 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | ovarian carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00825201 | First Line Tx Stage III Ovarian Cancer | peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT01935492 | 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
NCT01324076 | Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | liver cancer | Doxorubicin (NPC261012) | NP level |
NCT04982237 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT01847001 | Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01100944 | A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies | Thymic Carcinoma;Thymoma | Doxorubicin (NPC261012) | NP level |
NCT01730833 | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | inflammatory breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00367471 | Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00137111 | Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
NCT03829722 | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | oropharynx squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01848132 | Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00006469 | Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00716534 | Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | diffuse large B-cell lymphoma;follicular lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00003784 | S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03517449 | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | endometrial neoplasm | Paclitaxel (NPC208553);Doxorubicin (NPC261012) | NP level |
NCT00001442 | A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer | squamous cell carcinoma;upper aerodigestive tract neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02603679 | Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02569242 | Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00404066 | Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02753881 | Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer | liver cancer | Doxorubicin (NPC261012) | NP level |
NCT05455918 | Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor | childhood germ cell tumor | Paclitaxel (NPC208553) | NP level |
NCT01650376 | Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer | uterine cancer | Paclitaxel (NPC208553) | NP level |
NCT00458315 | Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00066716 | Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00429299 | Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00753909 | Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01865110 | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01225523 | Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00563784 | TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00004137 | S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT01091428 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | fallopian tube cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT01003158 | Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | endometrioid carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03493854 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT02772822 | A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00080418 | Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00553462 | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00006108 | Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04077255 | EGFR-targeted Therapy for Gastric Cancer | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00154882 | Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | small cell lung carcinoma;non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00005649 | Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00473720 | Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers | cancer | Paclitaxel (NPC208553) | NP level |
NCT02135822 | Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma | gastric adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT00278148 | Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT02697838 | Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT02398240 | Brentuximab for Newly Diagnosed Hodgkin Disease | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | carcinoid tumor;endometrium neoplasm;gastric cancer;ovarian carcinoma;urinary bladder cancer | Paclitaxel (NPC208553) | NP level |
NCT03108300 | Use of Propranolol Hydrochloride in the Treatment of Metastatic STS | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
NCT00864318 | Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis | germ cell tumor | Paclitaxel (NPC208553) | NP level |
NCT05201248 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
NCT04460066 | A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT01802749 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00003326 | Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT01812369 | Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
NCT01388621 | Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
NCT00148681 | Preoperative Herceptin and Navelbine for Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00281788 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT01281943 | Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
NCT00003160 | Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | fallopian tube cancer;ovarian cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT01930292 | Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02392507 | A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00550771 | German Preoperative Adriamycin Docetaxel Study | breast neoplasm | Doxorubicin (NPC261012) | NP level |
NCT00003392 | High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT01367002 | Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer | endometrial cancer | Paclitaxel (NPC208553) | NP level |
NCT01821859 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT04498689 | Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02181738 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT02250326 | Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02446574 | Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma | esophageal carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00075270 | Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT00986674 | Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04938583 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT01980472 | Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00251095 | Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer | breast neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03892018 | The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol | neoplasm | Paclitaxel (NPC208553) | NP level |
NCT03126812 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT04692051 | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | biliary tract cancer | Paclitaxel (NPC208553) | NP level |
NCT00016276 | Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer | inflammatory breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01083537 | Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer | fallopian tube cancer;peritoneum cancer | Paclitaxel (NPC208553) | NP level |
NCT00719472 | A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03944304 | Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | gastrointestinal stromal tumor | Paclitaxel (NPC208553) | NP level |
NCT01457846 | Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer | gastric cancer | Paclitaxel (NPC208553) | NP level |
NCT00003128 | Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus | sarcoma | Paclitaxel (NPC208553) | NP level |
NCT00874848 | Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00355199 | Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01146795 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | ovarian cancer | Paclitaxel (NPC208553) | NP level |
NCT00433420 | Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT00299182 | Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00024375 | DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00008047 | Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT03646123 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
NCT01872403 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT05000892 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms | salivary gland cancer | Paclitaxel (NPC208553) | NP level |
NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | kidney cancer;lung neoplasm;metastasis | Paclitaxel (NPC208553) | NP level |
NCT04443348 | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT01566240 | Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer | cervical cancer | Paclitaxel (NPC208553) | NP level |
NCT00930605 | The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT00083538 | Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally | multiple myeloma | Doxorubicin (NPC261012) | NP level |
NCT00003943 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. | lung cancer;carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04469556 | Pancreatic Adenocarcinoma Signature Stratification for Treatment | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
NCT03515798 | Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer | inflammatory breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT04101812 | Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
NCT00064116 | Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
NCT03691090 | Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer | esophageal cancer | Paclitaxel (NPC208553) | NP level |
NCT00004077 | Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer | testicular neoplasm | Paclitaxel (NPC208553) | NP level |
NCT02685657 | Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
NCT00004924 | Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer | lung cancer | Paclitaxel (NPC208553) | NP level |
NCT00316199 | Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer | breast cancer | Paclitaxel (NPC208553) | NP level |
NCT04707118 | Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy | pancreatic carcinoma | Paclitaxel (NPC208553) | NP level |
NCT00111007 | A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma | melanoma | Paclitaxel (NPC208553) | NP level |
NCT02436993 | Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | breast carcinoma | Paclitaxel (NPC208553) | NP level |
NCT03964753 | Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma | esophageal squamous cell carcinoma | Paclitaxel (NPC208553) | NP level |
NCT01763671 | Paclitaxel-bevacizumab in Advanced Lung Cancer | non-small cell lung carcinoma | Paclitaxel (NPC208553) | NP level |
NCT02798536 | Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | mesothelioma | Paclitaxel (NPC208553) | NP level |
NCT00209209 | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
NCT04390763 | Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) | pancreatic ductal adenocarcinoma | Paclitaxel (NPC208553) | NP level |
How do we define the Plant-Targeted Human Disease Association?
Associated human diseases of an individual plant are summurized based on FOUR types of association evidence, these include:
❶ Association by Therapeutic Target: Bioactive protein targets of the plant were defined in "Molecular Targets" section, target-disease associations collected from TTD database were subsequently used to build the associations between the plant and its targeted human diseases.
❷ Association by Disease Gene Reversion: Plant and a specific disease will be associated when >= 1 plant target gene overlaped with disease's DEGs.
❸ Association by Clinical Trials of Plant: Plant and a specific disease will be associated when >= 1 clinical trial (the plant is the intervetion) can be matched in ClinicalTrials.gov database.
❹ Association by Clinical Trials of Plant Ingredients: Plant and a specific disease will be associated when >= 1 clinical trial (the plant ingredient is the intervetion) can be matched in ClinicalTrials.gov database.
Associated Disease of the Plant |
Association Type & Detailed Evidence |
---|---|
Diffuse large B-cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A81 |
TOP2A
NCT04517435,NCT04139304,NCT01148446,NCT04002947,NCT05290090,NCT05018520,NCT04824092,NCT05189197,NCT03274492,NCT03650933,NCT03003520,NCT01622439,NCT02285062,NCT03201471,NCT01009970,NCT03225924,NCT01848132,NCT04660799,NCT00140595,NCT04790903,NCT05428670,NCT02889523,NCT05179733,NCT01287741,NCT02792491,NCT01004991,NCT02617485,NCT00355199,NCT03399747,NCT00144807,NCT05422066,NCT03485118,NCT02951728,NCT00850512,NCT03018626,NCT02228512,NCT02428751,NCT02855359,NCT04023916,NCT04025593,NCT00575406,NCT00169130,NCT00135499,NCT00931918,NCT00499018,NCT01724021,NCT02753647,NCT02772822,NCT00268853,NCT02733380,NCT03943901,NCT02734771,NCT01925612,NCT04661007,NCT01285765,NCT04263584,NCT04594798,NCT01659099,NCT01415765,NCT02867566,NCT04231448,NCT01804127,NCT02596971,NCT05200312,NCT05498259,NCT03129828,NCT02449265,NCT02890602,NCT01852435,NCT05389423,NCT00582725,NCT05406401,NCT04835870,NCT00379574,NCT04332822,NCT04021992,NCT01649856,NCT05351346,NCT04529772,NCT04546620,NCT03758989,NCT01040871,NCT03536039,NCT01087424,NCT04974996,NCT02531308,NCT05234684,NCT02449278,NCT02054559,NCT01459887 |
Mature B-cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A85 |
TOP2A
NCT00054665,NCT00486759,NCT03467373,NCT02787239,NCT03677141,NCT00324467,NCT05201248,NCT04745949 |
Classical Hodgkin lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B30.1 |
NCT05008224,NCT03527628,NCT03004833,NCT03712202,NCT04624984,NCT02414568,NCT05404945,NCT02661503,NCT03233347
|
Neuroblastoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH85Z0 |
NCT01704716,NCT01857934,NCT03786783,NCT00135135,NCT04221035,NCT00186849,NCT00578864,NCT00808899,NCT02771743
|
Endometrioid adenocarcinoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH0SD2 |
NCT00989651,NCT01167712,NCT00262847,NCT00079430,NCT00466960,NCT00108745,NCT00002913,NCT02713386,NCT00085358
|
Adenocarcinoma of pancreasDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10.0 |
DHCR7,TUBB6,SLCO1B3,NPC1,PMP22,AURKA,ITGAV,F2,LMNA
|
Malignant neoplasms of stomachDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B72 |
NCT04563975,NCT04267549,NCT01136031,NCT02855788,NCT01641939,NCT05002686,NCT03766607,NCT04943653,NCT05410847,NCT04195828,NCT03263741,NCT04781413,NCT03704077,NCT04286711,NCT02229058,NCT04358341,NCT04135781,NCT01854255,NCT04602117,NCT00003862,NCT02442362,NCT05070598,NCT04258657,NCT04342910,NCT04182724,NCT02845908,NCT05190445,NCT01248403,NCT01015339,NCT05319639,NCT01063517,NCT05318794,NCT03475615,NCT04592211,NCT03801668,NCT01746771,NCT03977220,NCT03428425,NCT02890511,NCT05204173,NCT03751761,NCT01980810,NCT01249443,NCT00003298,NCT03026881,NCT04308837,NCT02697838,NCT02451956,NCT04683939,NCT03322969,NCT04149015,NCT04258644,NCT03286244,NCT05441254,NCT01183559,NCT03718624,NCT02038621,NCT01170663,NCT00209612,NCT01491217,NCT04155671,NCT01224652,NCT01283204,NCT00154726,NCT04001569,NCT01739894,NCT04526470,NCT03579784,NCT04888663,NCT05052931,NCT05427383,NCT04694183,NCT05025033,NCT05095467,NCT02072317,NCT05171530,NCT04835896,NCT01457846,NCT01924533,NCT02934464,NCT04483076,NCT02486601,NCT00661167,NCT02931890,NCT01471132,NCT05400915,NCT01839773,NCT02574663
|
Esophageal cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B70 |
NCT00230451,NCT00393068,NCT03328234,NCT02598687,NCT02607982,NCT00730353,NCT00006245,NCT00154700,NCT03126708,NCT00069953,NCT04540211,NCT00815308,NCT01034189,NCT00002984,NCT02279134,NCT01249443,NCT01998347,NCT02133612,NCT02861690,NCT01183559,NCT03279237,NCT00570531,NCT00003087,NCT05013697,NCT01704690,NCT02429622,NCT03281369,NCT00453323,NCT00154804,NCT00066716,NCT02461043,NCT02297217,NCT03490292,NCT02924909,NCT04426955,NCT00002711,NCT05357846,NCT02891083,NCT03731442,NCT03308552,NCT02389751,NCT01372202,NCT04821765,NCT00344552,NCT00686114,NCT04879368,NCT00016900,NCT00193141,NCT02446574,NCT04460066,NCT00655876,NCT02762474,NCT05174156,NCT02317991,NCT02569242,NCT02741856,NCT03691090,NCT00971841,NCT00139633,NCT02574663,NCT00107341,NCT04005170,NCT01843829,NCT02735239,NCT02858206,NCT02273713,NCT02570893,NCT00003326,NCT01444547,NCT00006472,NCT00021320,NCT02644863,NCT04046575,NCT00493025,NCT03165994,NCT04278287,NCT00008047,NCT03087864,NCT00281788,NCT04006041
|
Squamous cell carcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B60-2D01 |
NCT02350517,NCT01166542,NCT05189730,NCT03603756,NCT04354961,NCT05342636,NCT04767295,NCT03783442,NCT04472429,NCT03748134,NCT03940001,NCT02059967,NCT05125055,NCT04506138,NCT01225523,NCT05312372,NCT03866993,NCT00816634,NCT03957590,NCT00176254,NCT04764227,NCT00596830,NCT04138212,NCT05007145,NCT00001442,NCT01822613,NCT03116152,NCT03762564,NCT03946969,NCT04225364,NCT03964753,NCT04929041,NCT01591135,NCT05319730,NCT02459457,NCT04568200,NCT04804696,NCT02027428,NCT03719924,NCT00998192,NCT00753038,NCT00176267,NCT00042835,NCT01969955,NCT03430843,NCT02611700,NCT03278626,NCT05281003,NCT03387111,NCT02916511,NCT04460352,NCT04644250,NCT03292822,NCT04888403,NCT04807673,NCT04063683,NCT05213312,NCT03975270,NCT01258192,NCT05394415,NCT04718415,NCT01386385,NCT04949256,NCT05449483,NCT04937673,NCT04625543,NCT05322499,NCT01249443,NCT01688700,NCT02272699,NCT04390958,NCT04943445,NCT02976909,NCT01752205,NCT04844385,NCT02033538,NCT02784288,NCT02677597,NCT04084158,NCT04548440
|
Colorectal cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B91 |
ITGAV,TOP2A
NCT00625573,NCT03169777,NCT02103062,NCT02574663,NCT01730586,NCT00024401 |
AngiosarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B56 |
NCT04339738,NCT01042379,NCT04859465,NCT02212015,NCT01303497,NCT03512834,NCT01055028,NCT03544567
|
Urethral cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C93 |
NCT00479128,NCT00022191,NCT00003376,NCT00478361,NCT04579224,NCT00022633,NCT00005644,NCT00045630
|
HepatoblastomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.01 |
TRIM24,TOP2A,PMP22,AURKA,GMNN,TUBB3
NCT03017326,NCT04478292 |
Malignant neoplasms of cervix uteri, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C77.Z |
NCT05290935,NCT04188860,NCT04652076,NCT03556839,NCT02492503,NCT02595554,NCT02312804
|
Thyroid cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D10 |
NCT01701349,NCT02152137,NCT01882816,NCT00507429,NCT00786552,NCT03085056,NCT00603941
|
LeiomyosarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B58 |
NCT03420014,NCT04996004,NCT02131480,NCT00815945,NCT03437070,NCT02997358,NCT05099666
|
Biliary tract cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C17 |
NCT02632305,NCT03830606,NCT04004234,NCT05170438,NCT04492033,NCT04692051,NCT04027764
|
Transitional cell carcinoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH8EH1 |
NCT04211012,NCT03240016,NCT03871036,NCT03464734,NCT04603846,NCT02412670,NCT03197571
|
Malignant neoplasms of biliary tract, distal bile ductDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C15 |
TOP2A,TUBB6,PMP22,AURKA,GMNN,ITGAV,LMNA
|
Hepatocellular carcinoma of liverDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.02 |
AURKA,GMNN,TOP2A,TRIM24,AURKA,GMNN,TOP2A
|
Fallopian tube cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C74 |
NCT01204749,NCT00085358,NCT03635489,NCT03126812,NCT00466986,NCT01091428,NCT02050009,NCT02012192,NCT01253681,NCT00003160,NCT00373217,NCT00408070,NCT01666444,NCT01219777,NCT00075712,NCT01083537,NCT00006454,NCT00003624,NCT00993655,NCT00517621,NCT00672295,NCT00079430,NCT01493505,NCT02520154,NCT01100372,NCT01146795,NCT01447706,NCT03393884,NCT00008138,NCT01649336,NCT00189566,NCT00479817,NCT00052468,NCT00003064,NCT01196741,NCT00028743,NCT00031954,NCT03029611,NCT00903630,NCT01402271,NCT03462212,NCT01570582,NCT00003120,NCT03056833,NCT00226915,NCT00003896,NCT02834975,NCT00550784,NCT00189553,NCT00003944,NCT02865811,NCT00520013,NCT00091377,NCT00466960,NCT00652119,NCT00331422,NCT00003385,NCT00004934,NCT02713386,NCT03038100,NCT00838656,NCT00702299,NCT03740165,NCT00262990,NCT02121990,NCT00483782,NCT01220154,NCT02606305
|
Neoplasms of unknown behaviour of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2F95 |
NCT00353717,NCT03036488,NCT00779129,NCT01953536,NCT01572038,NCT04895358,NCT02776917,NCT03273595,NCT01205217,NCT00553358,NCT01026116,NCT00524303,NCT00251095,NCT03742102,NCT02307227,NCT00367471,NCT00048893,NCT00272987,NCT00075270,NCT00448305,NCT02455141,NCT01953445,NCT00525642,NCT02162719,NCT01779050,NCT03396445,NCT03678883,NCT02622074,NCT01271725,NCT03705429,NCT00174434,NCT00687440,NCT03997123,NCT00373256,NCT00194753,NCT00429299,NCT00550771,NCT00174707,NCT00388076,NCT01220128,NCT05244993,NCT00356811,NCT00849472,NCT00174655,NCT02051751,NCT00111787,NCT00191672,NCT04251533,NCT00121992,NCT00110695,NCT01138046,NCT00046514,NCT00021255,NCT03272477,NCT00543829,NCT05067530,NCT00446030,NCT00709761,NCT00246571,NCT00281658,NCT00201435,NCT01137994,NCT00046527,NCT00722293
|
AdenocarcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D40 |
NCT04469556,NCT02583477,NCT03345810,NCT02059967,NCT02048943,NCT01431794,NCT00042835,NCT04329949,NCT00201734,NCT04827953,NCT04634539,NCT02303977,NCT00005838,NCT02754726,NCT01218516,NCT04046887,NCT02426281,NCT03410030,NCT02243007,NCT03496662,NCT04481204,NCT00368992,NCT01253525,NCT01506973,NCT03908333,NCT02926183,NCT03697239,NCT05257993,NCT00384826,NCT02732938,NCT02501902,NCT01578551,NCT02186847,NCT03915444,NCT04581343,NCT00021060,NCT03361319,NCT02723331,NCT02101021,NCT02993731,NCT02047513,NCT00955305,NCT04929041,NCT03517176,NCT02468557,NCT04821284,NCT05042128,NCT00369551,NCT04390763,NCT02715804,NCT00040794,NCT04852367,NCT04935359,NCT04257448,NCT00002852,NCT05254171,NCT01676259,NCT00226746,NCT02487277,NCT04134468
|
Renal cell carcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C90 |
EPAS1,MTOR
NCT05092373,NCT00068393,NCT02419495,NCT00001383 |
Solid tumour/cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00-2F9Z |
MTOR,HIF1A,TOP2A,ITGAV,EPAS1,AURKA
|
Kaposi sarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B57 |
TOP2A
NCT00003350,NCT00002318,NCT00923936,NCT00002105,NCT02659930 |
CholangiocarcinomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH7M15 |
NCT02181634,NCT04683939,NCT02994251,NCT01963325,NCT04077983,NCT03943043
|
Adenocarcinoma, endocervical typeDisease Category: X.Extension CodesDisease ICD-11 Code: XH0GS9 |
NCT02020707,NCT04516616,NCT00064077,NCT04723875,NCT01755897,NCT00295789
|
GerminomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH1E13 |
NCT00864318,NCT02414685,NCT00611962,NCT04581265,NCT01873326,NCT05455918
|
Uterine ligament/parametrium/uterine adnexa neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C72 |
NCT00506779,NCT00584857,NCT00584909,NCT00147680,NCT01650376,NCT00231868
|
Urogenital cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C95-2C9Z |
NCT00034177,NCT02033993,NCT02256436,NCT02756013,NCT04527991,NCT00151034
|
Squamous cell carcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.2 |
TOP2A,SLCO1B3,AURKA,GMNN,F2,SLCO1B1
|
Mesothelioma of pleuraDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C26.0 |
DHCR7,TOP2A,NPC1,AURKA,GMNN,LMNA
|
Adenocarcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.0 |
TOP2A,SLCO1B3,AURKA,GMNN,F2,SLCO1B1
|
Unspecified malignant neoplasms of unspecified sitesDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D4Z |
NCT00798252,NCT00147225,NCT00954642,NCT01376310,NCT00002854,NCT01604863,NCT02327169,NCT02483247,NCT02138812,NCT01653470,NCT00881166,NCT02412722,NCT02366949,NCT02761694,NCT01688791,NCT03507491,NCT04196283,NCT01113476,NCT01636622,NCT00508326,NCT01235897,NCT01075464,NCT01192165,NCT01057264,NCT01633970,NCT02317419,NCT02251951,NCT01705483,NCT00703170,NCT01204996,NCT01325441,NCT00337376,NCT02240212,NCT01110603,NCT03328494,NCT00305084,NCT01301716,NCT00113438,NCT05235542,NCT01579578,NCT02640755,NCT01351350,NCT00507962,NCT00124956,NCT02630199,NCT01497470,NCT05081609,NCT02383212,NCT03498521,NCT04632992,NCT01187199,NCT01374620,NCT00473720,NCT02892123,NCT00358163,NCT01015222,NCT02193633,NCT00581971,NCT00608803
|
Malignant neoplasms of retroperitoneumDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C50 |
NCT00084448,NCT01649336,NCT00003120,NCT00466960,NCT00550784,NCT00702299,NCT00483782,NCT00003160,NCT01402271,NCT00003896,NCT02834975,NCT00004934,NCT00003998,NCT00017303,NCT00085358,NCT03126812,NCT00003624,NCT00003385,NCT00008138,NCT00002734,NCT00652119,NCT00408070,NCT02865811,NCT02050009,NCT00903630,NCT01821859,NCT01493505,NCT00003322,NCT00331422,NCT00091377,NCT00005026,NCT00373217,NCT00079430,NCT00002894,NCT00672295,NCT01447706,NCT00003944,NCT02020707,NCT00031954,NCT00993655,NCT01083537,NCT01100372,NCT02272790,NCT00825201,NCT00491855,NCT00028743,NCT00075712,NCT00002717,NCT00838656,NCT01091428,NCT00003378,NCT00003064,NCT00023907,NCT00005046,NCT00003880
|
Cervical cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C77 |
NCT01487226,NCT04016142,NCT00276796,NCT04868708,NCT04799639,NCT04238988,NCT02432365,NCT01667211,NCT04864782,NCT03635567,NCT01566240,NCT04974944,NCT02036164,NCT02422563,NCT00057928,NCT04150575,NCT00626561,NCT00340184,NCT03340376,NCT00003624,NCT03367871,NCT00002949,NCT00003377,NCT04551950,NCT04341883,NCT00997009,NCT04806945,NCT01755845,NCT01756170,NCT03534713,NCT00003065,NCT04982237,NCT03852979,NCT02446652,NCT01229930,NCT00823186,NCT00980954,NCT05179239,NCT04884906,NCT02039791,NCT05367206,NCT03912402,NCT00462397,NCT00003379,NCT05247619,NCT00138151,NCT01405235,NCT04973904,NCT01594099,NCT03912415,NCT02467907,NCT04731038
|
Head and neck cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D42 |
MTOR
NCT00176241,NCT01333085,NCT00971867,NCT00004089,NCT02013453,NCT00025298,NCT00100789,NCT04883281,NCT00022217,NCT00089297,NCT00002922,NCT00566540,NCT00301028,NCT00005647,NCT00083057,NCT00959387,NCT00003251,NCT00997906,NCT01024101,NCT00002632,NCT01911598,NCT00337532,NCT00004865,NCT00319839,NCT00113399,NCT00011999,NCT03887442,NCT01264328,NCT00833261,NCT00003206,NCT01084083,NCT00006248,NCT00851877,NCT00004094,NCT01126216,NCT00270790,NCT00003592,NCT04338399,NCT00003193,NCT00392704,NCT01412229,NCT00005087,NCT00855764,NCT00002888,NCT00003327,NCT00731380,NCT00004097,NCT00343083,NCT00014118 |
Pulmonary hypertensionDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BB01 |
MTOR,HIF1A
NCT01246193,NCT01352689,NCT01340131 |
Pleural mesotheliomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C26 |
MTOR
NCT00634205,NCT02798536,NCT00859495,NCT00886028 |
Malignant neoplasms of oesophagusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B70 |
SLCO1B1,AURKA,TOP2A,SLCO1B3
NCT02395705 |
Testicular cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C80 |
NCT00231582,NCT00104676,NCT00531687,NCT00072215,NCT00004077
|
ovarian cystadenocarcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73.Y |
NCT00085358,NCT00466960,NCT00002913,NCT02050009,NCT00079430
|
Malignant neoplasms of stomach, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B72.Z |
NCT04714190,NCT00881816,NCT03081143,NCT00639522,NCT02163291
|
Adenocarcinoma of prostateDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C82.0 |
SLCO1B1,SLCO1B3
NCT04221828,NCT00521781,NCT02560051 |
OsteosarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B51 |
NCT00180908,NCT00586846,NCT00691236,NCT01258634,NCT00145639
|
Carcinosarcoma of uterusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76.43 |
DHCR7,TOP2A,GMNN
NCT00954174,NCT00687687 |
Malignant neoplasms of corpus uteriDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76 |
NCT00063999,NCT00505492,NCT01970722,NCT02112552,NCT02684227
|
Serous cystadenoma,borderline malignancy of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73.4 |
SLCO1B3,AURKA,GMNN,TUBB3,THRB
|
Superficial ovarian endometriosisDisease Category: 16.Diseases of the genitourinary systemDisease ICD-11 Code: GA10.B4 |
TUBB6,PMP22,TUBB3,LMNA,RAB9A
|
Urothelial carcinoma of bladderDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C94.2 |
DHCR7,TOP2A,SLCO1B3,AURKA,SLCO1B1
|
Glioblastoma of brainDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00.00 |
TUBB6,GMNN,ITGAV,LMNA,RAB9A
|
Germ cell tumour of testisDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C80.2 |
GMNN,F2,THRB,RAB9A,SLCO1B1
|
Malignant neoplasms of adrenal glandDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D11 |
DHCR7,TOP2A,AURKA,GMNN,TUBB3
|
Multiple myelomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A83 |
MTOR
NCT00750815,NCT00003399,NCT01078441,NCT01541332,NCT00215943,NCT04877275,NCT00706953,NCT02471820,NCT00814541,NCT00441168,NCT00083915,NCT00925821,NCT00574080,NCT00516191,NCT01246063,NCT01492881,NCT01548573,NCT00083551,NCT01394354,NCT00734877,NCT00319865,NCT00572169,NCT02075021,NCT00003853,NCT02186834,NCT01177683,NCT00003401,NCT00148317,NCT00366106,NCT01328236,NCT01889420,NCT01215344,NCT00617591,NCT01481194,NCT02362165,NCT00871013,NCT02985333,NCT01646762,NCT01101594,NCT03004287,NCT01070862,NCT00869232,NCT00083538 |
Breast in situ carcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E65 |
NCT02654119,NCT03725436,NCT01498588,NCT05422794,NCT05177796,NCT02672475,NCT01885013,NCT01091428,NCT03101748,NCT03164993,NCT00785291,NCT04081389,NCT01935492,NCT02419495,NCT01750073,NCT04266249,NCT02187991,NCT01263145,NCT02593175,NCT04001829,NCT02883062,NCT04216472,NCT03971409,NCT01275677,NCT00542451,NCT05092373,NCT03201861,NCT05233696,NCT01463072,NCT02436993,NCT03853707,NCT02632071,NCT02689427,NCT03554044,NCT04862585,NCT03606967,NCT02474173,NCT00520975,NCT01238133,NCT02603679,NCT04249167,NCT03179904
|
Soft tissue disorderDisease Category: 15.Diseases of the musculoskeletal system or connective tissueDisease ICD-11 Code: FB56 |
NCT02049905,NCT05448820,NCT05100628,NCT01440088,NCT05189483,NCT04656262,NCT03719430,NCT00755261,NCT00102609,NCT03317457,NCT00878800,NCT04757337,NCT03283696,NCT03042819,NCT04776525,NCT03056001,NCT03805022,NCT00502411,NCT04032964,NCT04874311,NCT01168791,NCT00790244,NCT02451943,NCT02784015,NCT04650984,NCT04780464,NCT04012827,NCT00017160,NCT02255110,NCT00484341,NCT01861951,NCT03524898,NCT00626704,NCT00718484,NCT04910126,NCT03698227,NCT03108300,NCT01514188,NCT04765228,NCT02783599
|
Brain cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00 |
TOP2A,EPAS1,HIF1A
NCT01014767 |
Malignant haematopoietic neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B33 |
MTOR,AURKA,TOP2A
NCT00051311 |
Acute myeloid leukaemiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A60 |
AURKA,TOP2A
NCT03860844,NCT03059615 |
Glioblastoma, primary, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH0MB1 |
NCT01851733,NCT00944801,NCT02372409,NCT00479765
|
Ewing sarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B52 |
NCT00038142,NCT01864109,NCT02063022,NCT00568464
|
Adult T-cell lymphoma or leukaemia, human T-cell lymphotropic virus type 1-associatedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90.5 |
NCT01788137,NCT01000285,NCT02228772,NCT03007147
|
Angioimmunoblastic T-cell lymphomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH1J86 |
NCT00725231,NCT03853044,NCT00169156,NCT01719835
|
Thymic carcinoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH6AK2 |
NCT00818090,NCT00010257,NCT03694002,NCT01100944
|
Burkitt lymphoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH4KA9 |
NCT05270057,NCT00126191,NCT00669877,NCT05389423
|
Squamous cell carcinoma of oropharynxDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B6A.0 |
NCT05108870,NCT04718415,NCT03829722,NCT04572100
|
Large cell carcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.3 |
NCT02186847,NCT03345810,NCT00596830,NCT00955305
|
Other specified malignant neoplasms of kidney, except renal pelvisDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C90.Y |
TOP2A,F2,TOP2A
NCT04322318 |
Other specified malignant neoplasms of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.Y |
TOP2A,SLCO1B3,AURKA,TUBB3
|
Renal cell carcinoma, chromophobe typeDisease Category: X.Extension CodesDisease ICD-11 Code: XH6153 |
DHCR7,TOP2A,NPC1,AURKA
|
Endometrial cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76 |
MTOR
NCT00006027,NCT01767155,NCT02630823,NCT04159155,NCT01770171,NCT02744898,NCT04652076,NCT02476955,NCT05481645,NCT00022620,NCT00002949,NCT03932409,NCT00401635,NCT00003127,NCT00003624,NCT00052312,NCT01367002,NCT01100359,NCT04527900,NCT00373620,NCT03603184,NCT03935256,NCT02730416,NCT00016341,NCT05092373,NCT00879359,NCT00515073,NCT00411138,NCT00003691,NCT05489848,NCT00883116,NCT05201547,NCT00006377,NCT03503786,NCT03189446,NCT00513786,NCT00334321,NCT01244789 |
Hodgkin lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B30 |
NCT01652261,NCT00443677,NCT03755804,NCT01569204,NCT00795613,NCT02979522,NCT03159897,NCT02247869,NCT01251107,NCT01468740,NCT00816959,NCT00784537,NCT03646123,NCT02298283,NCT02505269,NCT01358747,NCT01555853,NCT00797472,NCT00038558,NCT00225173,NCT03618550,NCT01056679,NCT02398240,NCT03407144,NCT01356680,NCT00026208,NCT01060904,NCT01712490,NCT01929941,NCT01920932,NCT03033914,NCT04638790,NCT03517137,NCT02292979,NCT00736320,NCT02181738,NCT04685616,NCT02275598,NCT00512980
|
Precursor cell lymphoblastic leukaemia, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH5J37 |
NCT03023046,NCT01887587,NCT00131027,NCT00187161,NCT05453500,NCT03150693,NCT00549848,NCT00968253,NCT00440726,NCT03020030,NCT03817320,NCT01186328,NCT02881086,NCT01324180,NCT03384654,NCT03117751,NCT04307576,NCT03553238,NCT03991884,NCT00476190,NCT03860844,NCT02419755,NCT03349281,NCT00890656,NCT00671658,NCT00973752,NCT00439296,NCT01523977,NCT00600977,NCT00136435,NCT03515200,NCT03571321,NCT00137111,NCT05303792,NCT02420717,NCT04996160,NCT03643276,NCT00165087,NCT00165178
|
Breast cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C60-2C6Y |
TOP2A,AURKA,MTOR
NCT00334802,NCT00110084,NCT03805399,NCT00003440,NCT00721747,NCT04177108,NCT02641847,NCT04172259,NCT00093795,NCT01008150,NCT00005581,NCT01003158,NCT03595592,NCT01940497,NCT00532857,NCT01204801,NCT05020860,NCT05192798,NCT05346107,NCT00256243,NCT00004092,NCT00574587,NCT00191854,NCT02032277,NCT00903656,NCT00645177,NCT00724386,NCT00336791,NCT00136539,NCT00003013,NCT04159818,NCT04584112,NCT04024462,NCT00431795,NCT00312208,NCT00301730,NCT04083963,NCT00591851,NCT00003992,NCT00072319,NCT00688740,NCT01120171,NCT00236899,NCT03994107,NCT00559845,NCT00408408,NCT00024102,NCT00777673,NCT00667251,NCT00002953,NCT00003612,NCT00876395,NCT01784120,NCT00476827,NCT00675259,NCT00006120,NCT00426556,NCT00193037,NCT00793377,NCT00654836,NCT05390710,NCT04498793,NCT00007904,NCT00346229,NCT04540692,NCT03125902,NCT00691379,NCT04443348,NCT00194792,NCT00193206,NCT00154882,NCT00403130,NCT04664972,NCT01847001,NCT03725059,NCT00003088,NCT03409198,NCT01593020,NCT00513292,NCT00274456,NCT00129389,NCT00455533,NCT00795899,NCT00303108,NCT00022230,NCT03285607,NCT00486668,NCT00499525,NCT01206881,NCT00193115,NCT04138719,NCT00039546,NCT00691912,NCT00290732,NCT00915603,NCT00820170,NCT00622466,NCT00609791,NCT05491694,NCT00254592,NCT02413320,NCT00456846,NCT00404404,NCT00028990,NCT00479856,NCT04770272,NCT00070278,NCT00004067,NCT00001498,NCT00050167,NCT00944047,NCT00616967,NCT04213898,NCT00394251,NCT00707707,NCT00331630,NCT00580333,NCT00314977,NCT00003782,NCT00005800,NCT00206466,NCT00266799,NCT00016406,NCT00574236,NCT00102219,NCT00068757,NCT00589238,NCT01998906,NCT00971945,NCT01227408,NCT00934895,NCT00629499,NCT02897700,NCT04038489,NCT03575520,NCT00561119,NCT01818063,NCT00003165,NCT03197935,NCT00445458,NCT00003352,NCT01415336,NCT00096343,NCT01131364,NCT05159193,NCT03726879,NCT05207514,NCT00723125,NCT00618826,NCT00511459,NCT03933319,NCT00912444,NCT03301350,NCT05113251,NCT00434031,NCT00003086,NCT00002772,NCT00789581,NCT00887575,NCT00915018,NCT04243616,NCT00919880,NCT00637897,NCT00194779,NCT01333423,NCT03493854,NCT00006459,NCT01547741,NCT00014222,NCT00002627,NCT03071926,NCT00001384,NCT00900627,NCT01270373,NCT00756470,NCT00856492,NCT00668616,NCT00532285,NCT01964391,NCT01329627,NCT00316199,NCT00467012,NCT00542191,NCT02790580,NCT00006256,NCT00107094,NCT00003035,NCT00006108,NCT00499122,NCT00002628,NCT01176799,NCT00679029,NCT00807859,NCT00788931,NCT05227664,NCT00004125,NCT00951665,NCT00149214,NCT05088057,NCT04293393,NCT01396655,NCT00846027,NCT00680758,NCT00503750,NCT04129996,NCT00536939,NCT00436566,NCT05112536,NCT03949634,NCT00397761,NCT02506777,NCT00370552,NCT00006110,NCT00041119,NCT00002826,NCT00003972,NCT02850419,NCT04148911,NCT03425656,NCT02315196,NCT03057600,NCT00448591,NCT01042379,NCT00434356,NCT01669239,NCT00146549,NCT00250874,NCT01670500,NCT01354522,NCT02379585,NCT00002707,NCT01009983,NCT05097248,NCT00482391,NCT00394082,NCT00251472,NCT00128856,NCT03497702,NCT02562378,NCT00004174,NCT00201708,NCT01622361,NCT02132949,NCT00773695,NCT00930930,NCT04958785,NCT03872791,NCT00748553,NCT01646034,NCT00392392,NCT03002103,NCT00503906,NCT00295893,NCT04762901,NCT00669773,NCT03609047,NCT00019812,NCT01990352,NCT00563953,NCT00404066,NCT00983424,NCT00915369,NCT03412643,NCT00191789,NCT00567554,NCT00479674,NCT00365365,NCT00258960,NCT02472353,NCT00146562,NCT00129922,NCT00140140,NCT00054028,NCT01969032,NCT00002662,NCT05498896,NCT01672671,NCT00278109,NCT00433420,NCT02685657,NCT00475670,NCT00009997,NCT00629278,NCT00465673,NCT00636441,NCT00129376,NCT02838225,NCT00356681,NCT00148681,NCT02096588,NCT01881230,NCT00887536,NCT00524810,NCT00912639,NCT00005649,NCT00442260,NCT00530101,NCT00768859,NCT00546156,NCT00499603,NCT00499083,NCT02995772,NCT00096668,NCT00025688,NCT00093145,NCT02938442,NCT00960960,NCT00041470,NCT00618657,NCT00733408,NCT04085276,NCT00082095,NCT00448266,NCT00038402,NCT00003539,NCT00070564,NCT01966471,NCT00196872,NCT00003392,NCT00212082,NCT00031876,NCT00407888,NCT00431080,NCT00206518,NCT01090128,NCT00533936,NCT00493870,NCT01172223,NCT02299999,NCT00320541,NCT00123929,NCT00004013,NCT00003927,NCT00203372,NCT00544232,NCT02215876,NCT04296175,NCT05386524,NCT00028873,NCT00052351,NCT02499367,NCT00009763,NCT03329378,NCT00001383,NCT00635050,NCT01057069,NCT00003050,NCT01210768,NCT02488564,NCT03248427,NCT01796197,NCT00600340,NCT00003877,NCT00803556,NCT05275777,NCT00002679,NCT03742986,NCT02605915,NCT00322400,NCT00590785,NCT00289263,NCT02053597,NCT01959490,NCT01358877,NCT00717340,NCT00003042,NCT00002837,NCT01705691,NCT00607438,NCT00087178,NCT00002937,NCT00365417,NCT00311636,NCT00662129,NCT03498716,NCT00378313,NCT04301739,NCT00005635 |
Pleomorphic sarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B54 |
MTOR
NCT03802071,NCT03678883,NCT05210374,NCT00003054,NCT00204646,NCT02732015,NCT03880695,NCT04199026,NCT01027910,NCT01605526,NCT00189137,NCT00112489,NCT00020449,NCT02326025,NCT02448537,NCT01185964,NCT00949325,NCT00288431,NCT02812654,NCT01104298,NCT00003624,NCT04535713,NCT00217607,NCT00003128,NCT00796120,NCT00204568,NCT01746238,NCT00003008,NCT00001300,NCT04968106 |
Malignant neoplasm metastasis in lymph nodes of head, face or neckDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D60.0 |
F2,SLCO1B1,AURKA,SLCO1B3
NCT02573493,NCT05272696,NCT04843098,NCT00513383,NCT04826679,NCT04831320,NCT01732640,NCT04164238,NCT01612351,NCT03169764,NCT04807140,NCT03723967,NCT05283226,NCT03830385,NCT01852292,NCT05189184,NCT04882462,NCT05459129,NCT02124707,NCT04282109,NCT04278092,NCT01154920,NCT04428151,NCT00736944,NCT02270814,NCT05294900,NCT05054439 |
Malignant neoplasms of bladder, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C94.Z |
NCT00003133,NCT00136175,NCT00635726,NCT00028860,NCT00002949,NCT00022191,NCT02302807,NCT00506155,NCT04060459,NCT02177695,NCT05328336,NCT00585689,NCT04101812,NCT00006118,NCT00002917,NCT01812369,NCT00022633,NCT00045630,NCT00005644,NCT00003105,NCT00583349,NCT00003701,NCT00310011,NCT00003930,NCT00003342,NCT04602117,NCT00003376,NCT00055601,NCT00808639,NCT00268450,NCT00933374
|
Prostate cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C82 |
AURKA,MTOR
NCT00024414,NCT02494713,NCT00284752,NCT00003614,NCT00005028,NCT00151060,NCT00003717,NCT01558492,NCT00038168,NCT00193193,NCT00933426,NCT00176293,NCT00004054,NCT00005847,NCT00030654,NCT00003394,NCT00003084,NCT00028769,NCT01240629,NCT00016913,NCT00009750,NCT00049257,NCT02911350,NCT00005048,NCT04148885,NCT00084565,NCT00038246,NCT00003622 |
Multiple sclerosisDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A40 |
F2,TOP2A,ITGAV
|
ThymomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C27 |
NCT00818090,NCT01100944,NCT00010257
|
Rhabdomyosarcoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH0GA1 |
NCT04625907,NCT01871766,NCT04213794
|
Hereditary breast and ovarian cancer syndromeDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C65 |
NCT02978495,NCT05485766,NCT00535119
|
Malignant mixed epithelial mesenchymal tumour of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B5D.0 |
NCT01249443,NCT02822157,NCT02107937
|
Gastrointestinal stromal tumourDisease Category: X.Extension CodesDisease ICD-11 Code: XH9HQ1 |
NCT03944304,NCT02574663,NCT02607332
|
Malignant neoplasms of kidney, except renal pelvisDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C90 |
NCT03678883,NCT00077129,NCT00024388
|
Intrahepatic cholangiocarcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.10 |
NCT04175912,NCT03579771,NCT02392637
|
Mixed tumour, malignant, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH0V86 |
NCT01969578,NCT05000892,NCT04825938
|
Central nervous system diseaseDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A04-8D87 |
NCT00014573,NCT00002814,NCT00031577
|
Other specified malignant neoplasms ofcolonDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B90.Y |
SLCO1B3,F2,SLCO1B1
|
MelanomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C30 |
NCT01009515,NCT02023710,NCT00329641,NCT00970996,NCT01006252,NCT01676649,NCT00111007,NCT03167177,NCT00288041,NCT01200342,NCT01704287,NCT00483301,NCT04979585,NCT00796991,NCT00522834,NCT00864253,NCT01039844,NCT00434252,NCT00093119,NCT01827111,NCT02300935,NCT00084214,NCT01174238,NCT01666418,NCT00255762,NCT00462423,NCT00779714,NCT01107665,NCT02617849
|
Malignant lymphoma, not elsewhere classifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B33.5 |
NCT00184002,NCT00038545,NCT05238064,NCT01777152,NCT03467373,NCT00323323,NCT00825149,NCT03169790,NCT00455897,NCT00193440,NCT03013218,NCT00324467,NCT01746173,NCT00201318,NCT00133302,NCT02626455,NCT02055820,NCT01200758,NCT01332968,NCT02406092,NCT00361621,NCT03571308,NCT00088530,NCT00719472,NCT01555853,NCT01516580,NCT00809341
|
Hepatocellular carcinoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH4W48 |
NCT01381211,NCT00057382,NCT03008512,NCT00990860,NCT00471965,NCT01116635,NCT01327521,NCT01655693,NCT01281943,NCT05093920,NCT01004978,NCT03563170,NCT01966133,NCT03937830,NCT01840592,NCT05092373,NCT00877071,NCT00988195,NCT00108953,NCT02958163,NCT00083226,NCT01858207,NCT03145558,NCT04175912,NCT02527772,NCT03192644
|
Ovarian cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73 |
TOP2A
NCT00002928,NCT02098343,NCT03246074,NCT03126812,NCT03161132,NCT01666444,NCT00937560,NCT03635489,NCT00228319,NCT03776812,NCT03335241,NCT01838538,NCT00483782,NCT02159820,NCT01239732,NCT03467178,NCT00003064,NCT01379989,NCT04729387,NCT03806049,NCT01357161,NCT00550784,NCT00003624,NCT04887961,NCT01204749,NCT04337632,NCT01485848,NCT00610792,NCT00945191,NCT01653912,NCT00004921,NCT00002894,NCT00976911,NCT03989336,NCT05255471,NCT05316376,NCT01696032,NCT00825201,NCT00702299,NCT01637532,NCT00738699,NCT00390611,NCT00326456,NCT00017303,NCT00063401,NCT00158379,NCT00034151,NCT01802749,NCT03737643,NCT02421588,NCT00193297,NCT04908787,NCT03539328,NCT05467670,NCT00002734,NCT00003160,NCT00861120,NCT02312661,NCT00408070,NCT01253681,NCT00886717,NCT01113957,NCT00003449,NCT03596281,NCT02470585,NCT00189371,NCT00652119,NCT00004934,NCT04679064,NCT02865811,NCT01711970,NCT01649336,NCT01332656,NCT00170664,NCT00189553,NCT00585052,NCT01493505,NCT01954355,NCT01220154,NCT00003896,NCT02606305,NCT00006454,NCT04661696,NCT02431559,NCT02092363,NCT01654146,NCT00660842,NCT01684878,NCT00750386,NCT01219777,NCT00391118,NCT00005046,NCT00028743,NCT05145218,NCT01083537,NCT00226915,NCT00672295,NCT00003944,NCT00008138,NCT00052468,NCT00610714,NCT03763123,NCT04261465,NCT02121990,NCT02004093,NCT02001272,NCT00889382,NCT00401674,NCT02475772,NCT00314678,NCT00003214,NCT00005051,NCT00003998,NCT01358071,NCT03940196,NCT04815408,NCT01570582,NCT01100372,NCT01778803,NCT01196741,NCT00075712,NCT00002568,NCT00189566,NCT00003732,NCT00001383,NCT03901118,NCT00523380,NCT01388621,NCT00838656,NCT00031954,NCT00023907,NCT00003413,NCT00002819,NCT00003644,NCT04590625,NCT05044871,NCT01016054,NCT01644825,NCT03056833,NCT00929162,NCT00003733,NCT04931342,NCT04608409,NCT03287271,NCT03699449,NCT02125513,NCT02718417,NCT00758732,NCT00373217,NCT00102622,NCT00005026,NCT00003385,NCT02948075,NCT02545010,NCT00490711,NCT00091377,NCT00003120,NCT00002717,NCT04729608,NCT02520154,NCT02389985,NCT02834975,NCT03804866,NCT00520013,NCT02440425,NCT03197584,NCT01809379,NCT04348032,NCT00903630,NCT03394885,NCT03393507,NCT01650376,NCT00517621,NCT00993655,NCT00657878,NCT00003386,NCT00003880,NCT00722592,NCT05145569,NCT02483104,NCT02766582,NCT04072263,NCT01227941,NCT00011986,NCT00003378,NCT04921527,NCT03025477,NCT03410784,NCT00466986,NCT01146795,NCT01081951,NCT00084448,NCT00005612,NCT01821859,NCT05371301,NCT03740165,NCT04000295,NCT03038100,NCT00484432,NCT00331422,NCT01739218,NCT03029611,NCT02012192,NCT00635193,NCT04938583,NCT03818282,NCT00129727,NCT00964626,NCT02383251,NCT03639246,NCT02476955,NCT00231075,NCT00479817,NCT03942068,NCT01402271,NCT00262990,NCT00179725,NCT03393884,NCT00772798,NCT00003322,NCT02157870,NCT03398655,NCT03117933,NCT00840450,NCT04374630,NCT01705158,NCT01447706 |
Malignant neoplasms of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73 |
NCT00628251,NCT04711161,NCT00069901,NCT03314740,NCT01279291,NCT00001272,NCT00001426,NCT00653952,NCT00919984,NCT00659178,NCT01616303,NCT01121406,NCT01608009,NCT02751918,NCT02903004,NCT00248248,NCT00350948,NCT03574779,NCT00191646,NCT00913835,NCT00780039,NCT04561817
|
Small cell carcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.1 |
NCT00527735,NCT04210037,NCT04314895,NCT02262897,NCT04698941,NCT03810872,NCT00617409,NCT02769832,NCT05420636,NCT01441349,NCT00454324,NCT03219762,NCT04247126,NCT04056949,NCT02566993,NCT04672928,NCT02261805,NCT02551432,NCT02038647,NCT00317200,NCT00483509,NCT04213937
|
Adenocarcinoma of stomachDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B72.0 |
TOP2A,SLCO1B3,AURKA,F2,SLCO1B1
NCT02449655,NCT03990103,NCT01336062,NCT03193918,NCT04510064,NCT04077255,NCT01641783,NCT04047004,NCT04209686,NCT02448329,NCT04604132,NCT03281369,NCT02615730,NCT04572542,NCT04190745,NCT02625623 |
Non-small cell lung cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25 |
NCT00085839,NCT00832819,NCT00966914,NCT00147537,NCT00933803,NCT00097227,NCT01160601,NCT01711697,NCT00322452,NCT01196234,NCT02172846,NCT00762034,NCT00642759,NCT00508625,NCT00686322,NCT01236716,NCT00662597,NCT01090830,NCT00576225,NCT00437749,NCT01024062,NCT01649947,NCT01519804,NCT00948675,NCT01507428,NCT00654758,NCT00540514,NCT02016209,NCT02252796,NCT00850577,NCT00723957,NCT00152477,NCT00001499,NCT02419495,NCT02041533,NCT00268970,NCT00112294,NCT00006929,NCT01769391,NCT02403895,NCT01763671,NCT00702572,NCT02106546,NCT00071188,NCT02276560,NCT01872403,NCT01413750,NCT01179269,NCT00960297,NCT01364012,NCT01383148,NCT01310244,NCT00970580,NCT00343291,NCT00806286,NCT00168883,NCT00298415,NCT00480831,NCT00269828,NCT00005065,NCT02039674,NCT01820325,NCT01366131,NCT01560104,NCT00730925,NCT00874107,NCT00662311,NCT00291850,NCT00273507,NCT00198354,NCT02453282,NCT00318136,NCT00199758,NCT00050960,NCT00752115,NCT00254891,NCT00655850,NCT00198432,NCT02220894,NCT02367794,NCT01234038,NCT00976677,NCT00874848,NCT00473889,NCT00259675,NCT00073723,NCT00191256,NCT00034164,NCT00070629,NCT02083679,NCT02289456,NCT00800202,NCT00578149,NCT00861627,NCT00481078,NCT00300885,NCT02366143,NCT01980472,NCT02064491,NCT01249443,NCT00787852,NCT01199055,NCT00708812,NCT00687817,NCT00252798,NCT02477826,NCT01820754,NCT01966003,NCT01527864,NCT00915005,NCT00603538,NCT00369070,NCT00828841,NCT00753909,NCT00539331,NCT00061646,NCT00042302,NCT02259621,NCT01783197,NCT00702975,NCT00563784,NCT00527735,NCT00094835,NCT02142738,NCT02382406,NCT01496742,NCT00347412,NCT02182232,NCT02226757,NCT00460317,NCT01225302,NCT00686959,NCT00113516,NCT02117024,NCT02204345,NCT04224337,NCT02322281,NCT00866528,NCT00918203,NCT00735696,NCT00602797,NCT00768131,NCT00558636,NCT00434135,NCT00088556,NCT00088088,NCT02264990,NCT01454102,NCT02073968,NCT01836679,NCT00087802,NCT00903942,NCT01011075,NCT00034541,NCT02405910,NCT01268059,NCT00974584,NCT00680940,NCT00294762,NCT00093756,NCT00434226,NCT00049790,NCT00614484,NCT01620190,NCT03808480,NCT00716534,NCT01069328,NCT01702844,NCT02364999,NCT02250326,NCT01993810,NCT00001450,NCT01912625,NCT01326767,NCT00986674,NCT00035152,NCT01702714,NCT02420314,NCT01757288,NCT00807612,NCT00178256,NCT00449657,NCT01822496,NCT00313768,NCT01763645,NCT02392507,NCT02319889,NCT01303926,NCT00583830,NCT00198367,NCT00832494,NCT01158144,NCT00280787,NCT00174356,NCT01171170,NCT02412371,NCT00991796,NCT00666692,NCT01165216,NCT00161278,NCT01100931,NCT01493843
|
Carcinomas of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73.0 |
NCT05158062,NCT03598270,NCT03400306,NCT02419495,NCT02272790,NCT03030287,NCT00181701,NCT03542669,NCT01847677,NCT02107378,NCT05092373,NCT00312650,NCT03756818,NCT03690739,NCT01091428,NCT05446870,NCT01970722,NCT04602117,NCT02244502,NCT02437812
|
Pancreatic cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10 |
MTOR,TOP2A
|
Adrenomedullary hyperfunctionDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A75 |
HIF1A,EPAS1
|
AsthmaDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CA23 |
TOP2A,F2
|
ThrombosisDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DB61-GB90 |
TOP2A,F2
|
Bladder cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C94 |
MTOR,TOP2A
|
Pain, unspecifiedDisease Category: 21.Symptoms, signs or clinical findings, not elsewhere classifiedDisease ICD-11 Code: MG3Z |
MTOR
NCT02311907 |
PsoriasisDisease Category: 14.Diseases of the skinDisease ICD-11 Code: EA90 |
TOP2A
NCT00006276 |
Malignant neoplasms of other or unspecified parts of mouthDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B66 |
NCT00933387,NCT05456022
|
Skin cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C30-2C37 |
NCT03167164,NCT02054884
|
RetinoblastomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D02.2 |
NCT01783535,NCT00186888
|
Chronic arterial occlusive disease, unspecifiedDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BD4Z |
NCT03064126,NCT00518284
|
Carcinoma, undifferentiated, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH1YY4 |
NCT00108745,NCT00989651
|
Glioma, malignantDisease Category: X.Extension CodesDisease ICD-11 Code: XH4RQ3 |
NCT02861222,NCT03678883
|
Primary haemophagocytic lymphohistiocytosisDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4A01.23 |
NCT04077905,NCT02631109
|
strictureDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BB80.Z-LB15.1 |
NCT01868984,NCT02040454
|
Lymphoid leukaemia, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH7Q12 |
NCT00801580,NCT00866749
|
Chronic lymphocytic leukaemia or small lymphocytic lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A82.0 |
NCT00801281,NCT03003546
|
Anaplastic large cell lymphoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH1LC0 |
NCT01719835,NCT01309789
|
Ductal carcinoma in situ of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E65.2 |
NCT02779855,NCT00461344
|
Polyneuropathy, unspecifiedDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8C0Z |
NCT03492047,NCT00979082
|
NeutropeniaDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4B00 |
NCT04227990,NCT03294577
|
Penile cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C81 |
NCT04475016,NCT00512096
|
Systemic lupus erythematosusDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4A40.0 |
EPAS1,TUBB3
|
Malignant neoplasms of thymusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C27 |
TRIM24,GMNN
|
Invasive carcinoma of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C61 |
AURKA,TOP2A
|
Neuroendocrine carcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C34 |
NCT00894569,NCT00003558,NCT04705519,NCT00183742,NCT00731861,NCT00094497,NCT00001339,NCT00003943,NCT01593306,NCT00193531,NCT02215447,NCT03136055,NCT00936702,NCT01678664,NCT01253681,NCT00873119,NCT00737243,NCT00001569
|
Malignant neoplasms of nasopharynxDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B6B |
NCT04282070,NCT01712919,NCT01534585,NCT03047265,NCT04015661,NCT02250599,NCT00484601,NCT04850235,NCT03020329,NCT03306121,NCT03604965,NCT04004871,NCT01694576,NCT03574324,NCT03668730,NCT04223024,NCT04766359,NCT01797900
|
NeoplasmsDisease Category: 02.NeoplasmsDisease ICD-11 Code: 02 |
NCT00003130,NCT05322720,NCT02794571,NCT03834948,NCT02430311,NCT01293630,NCT01548924,NCT02379416,NCT00004863,NCT00350025,NCT03981796,NCT03600090,NCT04742036,NCT03617432,NCT04151277,NCT02134067,NCT00004173,NCT03907475,NCT00454649,NCT03894540,NCT03892018,NCT03430882,NCT00002939,NCT03085914,NCT00556088,NCT00003742,NCT05344742,NCT04336098,NCT00891605,NCT01297452,NCT00520000,NCT00030368,NCT00003555,NCT01148628,NCT03154294,NCT03057366,NCT02762981,NCT03309150,NCT00003004,NCT00095914,NCT00054548,NCT00819221,NCT04046016,NCT04794699,NCT01862328,NCT03693612,NCT00004979,NCT01240655,NCT00005819,NCT02607202,NCT01159418,NCT01968915,NCT01031212,NCT00087217,NCT00024310,NCT04761601,NCT03503604,NCT02715531,NCT02711137,NCT01248949,NCT00360360,NCT01525602,NCT00042809,NCT02051751,NCT05017012,NCT04594005,NCT01994031,NCT00100139,NCT00028587,NCT00496028,NCT00881101,NCT00003899,NCT02979392,NCT00768469,NCT01455532,NCT01362374,NCT00088114,NCT00422682,NCT04541108,NCT03577704,NCT01214668,NCT02593708,NCT03918278,NCT03330106,NCT00287937,NCT00016874,NCT00399126,NCT00046423,NCT04047862,NCT01938846,NCT01930292,NCT00809133,NCT00653939,NCT00009802,NCT03421353,NCT02937272,NCT01411410,NCT00009932,NCT01702129,NCT00001387,NCT02283489,NCT01566435,NCT03595059,NCT03588039,NCT02723955,NCT02377752,NCT00080418,NCT04481009,NCT00458315,NCT00811993,NCT00307255,NCT00001442,NCT00003242,NCT02630264,NCT03537690,NCT04675528,NCT05381909,NCT03023124,NCT03564691,NCT01419548,NCT04999969,NCT05262335,NCT01494688,NCT01491204,NCT01967043,NCT00006018,NCT00006257,NCT04176952,NCT04449549,NCT02057380,NCT00193596,NCT01992341,NCT01515306,NCT00607048,NCT03486314,NCT00009828,NCT00511849,NCT02341456,NCT04035473,NCT04802980,NCT04180384,NCT05214976,NCT02730481,NCT03601897,NCT00486954,NCT00005078,NCT00954512,NCT01593228,NCT00002587,NCT04143711,NCT01285466,NCT02317874,NCT02122770,NCT04778839,NCT00848718,NCT00793897,NCT01281176,NCT01946074,NCT02597036,NCT01617928,NCT00003092,NCT01868022,NCT03928314
|
Follicular lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A80 |
TOP2A
NCT00494780,NCT01650701,NCT00634179,NCT00715208,NCT01852435,NCT00907348,NCT02449252,NCT02889523,NCT05058404,NCT02855359,NCT05371093,NCT04745832,NCT00801281,NCT00774826,NCT01476787 |
Peripheral T-cell lymphoma, not otherwise specifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90.C |
NCT03542266,NCT04480099,NCT04922567,NCT00791947,NCT00725231,NCT01719835,NCT02445404,NCT01796002,NCT00930605,NCT00136565,NCT04569032,NCT01839097,NCT03952572,NCT03553537,NCT00970385,NCT03023358
|
Mantle cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A85.5 |
NCT00877006,NCT02858258,NCT00022945,NCT04566887,NCT00722137,NCT00581776,NCT02633137,NCT00209222,NCT05051891,NCT00878254,NCT00401817,NCT02427620,NCT00209209,NCT00477412,NCT01865110
|
Peritoneal cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C51 |
NCT02125513,NCT00001569,NCT00189566,NCT00262990,NCT03030287,NCT00391118,NCT00063401,NCT00517621,NCT03038100,NCT03056833,NCT01279291,NCT00191646,NCT00666991,NCT00189371,NCT03740165
|
Malignant neoplasm of pancreas, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10.Z |
NCT04158635,NCT02559674,NCT01461915,NCT03649321,NCT02109445,NCT00398086,NCT01621243,NCT02382263,NCT05047991,NCT01934634,NCT02767557,NCT02138383,NCT00882973,NCT01851174,NCT05251038,NCT04498689,NCT02005315,NCT03435289,NCT01836432,NCT03825328,NCT03487016,NCT00111904,NCT04814485,NCT03721744,NCT03136406,NCT02283372,NCT02050178,NCT03815461,NCT04683939,NCT02506803,NCT02514031,NCT03257033,NCT01647828,NCT01834235,NCT02391662,NCT02588443,NCT05346146,NCT01010945,NCT01088815,NCT04902261,NCT03941093,NCT04241276,NCT02930902,NCT02047500,NCT02241551,NCT02574663,NCT04203641,NCT01730222,NCT04054362,NCT02975141,NCT03278015,NCT01470417,NCT03563144,NCT02155088,NCT00323583,NCT05185869,NCT04617067,NCT04643405,NCT03086369,NCT03636308,NCT02873598,NCT02106884,NCT04674956,NCT03502343,NCT02608229,NCT01693276,NCT00691054,NCT04753879,NCT02207465,NCT02340117,NCT02651727,NCT00844649,NCT03417921,NCT02399137,NCT03329248,NCT02135822,NCT02358161,NCT00024375,NCT04390399,NCT04447092,NCT02581501,NCT03415802,NCT01964534,NCT02043730,NCT04581876,NCT03316599,NCT03641183,NCT02717091,NCT01978184,NCT05168527,NCT03412799,NCT03777462,NCT01632306,NCT01839487,NCT04683315,NCT05193604,NCT02210559,NCT03600623,NCT02570711,NCT04672005,NCT02109341,NCT02272738,NCT03989310,NCT04592861,NCT04247126,NCT04589234,NCT03336216,NCT03344172,NCT04723030,NCT00003591,NCT01858883,NCT05298020,NCT02506842,NCT04104672,NCT01822756,NCT05497778,NCT04858009,NCT00609765,NCT03693677,NCT02481635,NCT01893801,NCT01488552,NCT03797443,NCT04707118,NCT00426127,NCT03387098,NCT03519308,NCT02827201,NCT03714555,NCT02705196,NCT03850769,NCT03520790,NCT03252808,NCT02124317,NCT03885219,NCT03585062,NCT03586869,NCT05241249,NCT04089150,NCT05218889
|
Inflammatory carcinoma of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C62 |
NCT02125344,NCT03515798,NCT00016276,NCT00513695,NCT01583426,NCT02876302,NCT02199418,NCT02682693,NCT01730833,NCT02623972,NCT01938833,NCT02221999,NCT02879513,NCT05383196
|
Malignant neoplasms of corpus uteri, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76.Z |
TOP2A,SLCO1B3,AURKA,F2
NCT03517449,NCT03005015,NCT05173987,NCT04865289,NCT04269200,NCT04634877,NCT01820858,NCT03884101,NCT04602117,NCT02725268 |
Malignant neoplasm metastasis, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E2Z |
NCT02677116,NCT02419495,NCT00046423,NCT00731861,NCT00046527,NCT01721746,NCT00781612,NCT03678883,NCT00046514,NCT01014351,NCT00984464,NCT00048893,NCT02158520,NCT01933061
|
Malignant neoplasms of fallopian tube, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C74.Z |
NCT02125513,NCT02272790,NCT01167712,NCT00954174,NCT05092373,NCT03776812,NCT00391118,NCT02419495,NCT00063401,NCT03030287,NCT01279291,NCT01970722,NCT00191646
|
Carcinoma of male breastDisease Category: X.Extension CodesDisease ICD-11 Code: XH5KW8 |
NCT01281150,NCT00470301,NCT00770809,NCT01938833,NCT00861705,NCT01493310,NCT03018080,NCT01276496,NCT02060253,NCT00119262,NCT00368875,NCT01288261,NCT00513695
|
Lung cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25 |
AURKA,MTOR,TOP2A
NCT00003589,NCT00729612,NCT00025389,NCT00287989,NCT02733250,NCT00033696,NCT00017407,NCT00062010,NCT00004137,NCT03348904,NCT00096226,NCT01057342,NCT00003284,NCT01107626,NCT00290537,NCT00547443,NCT00032032,NCT00004160,NCT00728845,NCT00533949,NCT00193310,NCT00006012,NCT00003089,NCT00004055,NCT00063258,NCT00004202,NCT00054210,NCT00016315,NCT00006004,NCT00226590,NCT00144053,NCT00006374,NCT00006484,NCT00062179,NCT00004093,NCT00003812,NCT00278148,NCT00459121,NCT00276588,NCT00003117,NCT00003299,NCT00005032,NCT00002519,NCT00020007,NCT00005059,NCT00003313,NCT00006378,NCT00006229,NCT00193362,NCT00077246,NCT00039039,NCT00002972,NCT00465907,NCT01024712,NCT00043108,NCT00085501,NCT00006049,NCT00003387,NCT01285609,NCT04647344,NCT00550537,NCT00081302,NCT00005806,NCT00006469,NCT00003587,NCT00003317,NCT00551733,NCT00245154,NCT00452803,NCT00054392,NCT00004887,NCT02328105,NCT00533585,NCT00004011,NCT00004859,NCT00023673,NCT00003158,NCT00003281,NCT01486602,NCT00077220,NCT00004159,NCT00003881,NCT00616031,NCT00795340,NCT00334763,NCT00055887,NCT00011921,NCT00033410,NCT00079287,NCT00003159,NCT01862081,NCT00495170,NCT00033553,NCT00005849,NCT00748163,NCT00002969,NCT00004253,NCT00526890,NCT00453167,NCT00801736,NCT03322566,NCT00280150,NCT00004265,NCT00003696,NCT00025480,NCT00004126,NCT00003235,NCT00003943,NCT00979212,NCT00003111,NCT00028938,NCT00544648,NCT00005646,NCT02525653,NCT00062062,NCT00553462,NCT02044601,NCT02513563,NCT00807573,NCT00004924,NCT00661193,NCT00828009,NCT03432598,NCT02279732 |
Precursor B-lymphoblastic neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A70 |
NCT00866749,NCT02881086,NCT03817320,NCT03991884,NCT02228772,NCT05303792,NCT04043494,NCT02845882,NCT03564704,NCT03023046,NCT01451515,NCT01887587
|
LeukaemiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A60-2B33 |
NCT03975205,NCT01319981,NCT00072007,NCT01516580,NCT00038610,NCT00003230,NCT02723994,NCT00109837,NCT00003402,NCT00613457,NCT00003294
|
Melanoma of skin, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C30.Z |
NCT02419495,NCT00278122,NCT02020707,NCT02308553,NCT00081042,NCT00568451,NCT00976573,NCT00626405,NCT00404235,NCT02158520,NCT00110019
|
Mature T-cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90 |
MTOR,HIF1A,TOP2A
NCT00027937,NCT00003397,NCT00118209,NCT00004179,NCT00217425,NCT01404936,NCT01118026,NCT02359162,NCT00299182,NCT02529852,NCT00005584,NCT00265018,NCT00945724,NCT00854568,NCT00004057,NCT02012088,NCT00003389,NCT02605694,NCT00003578,NCT02918747,NCT00264953,NCT01831505,NCT01046825,NCT00554164,NCT03647072,NCT02670317,NCT04884035,NCT00003595,NCT00211185,NCT00893516,NCT00841945,NCT00003215,NCT05006664,NCT00064116,NCT00450801,NCT01321008,NCT01992653,NCT00536393,NCT00004112,NCT00008021,NCT00265031,NCT01855750,NCT00101101,NCT00005867,NCT03975205,NCT00002565,NCT04164368,NCT00060346,NCT04980222,NCT05075460,NCT00003957,NCT00003784,NCT01139359,NCT03435250,NCT00005021,NCT04856137,NCT00577629,NCT00369681,NCT01390584,NCT00787527,NCT01527422,NCT00021372,NCT00049595,NCT00770224,NCT00003402,NCT00060385,NCT00003541,NCT00003294,NCT00004916,NCT03188198,NCT00041210,NCT00003421,NCT00052936,NCT00974324,NCT00822120,NCT01490047,NCT00210379,NCT00041132,NCT00290498,NCT00451178,NCT00450385,NCT00003150,NCT01889069,NCT00504504,NCT00004010,NCT00577993,NCT00433433,NCT00001383,NCT01974440,NCT00002557,NCT00920153,NCT01414855,NCT00911183,NCT00009776,NCT03884556,NCT00006721,NCT01516567,NCT00004031 |
Liver cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12 |
MTOR,TOP2A,AURKA
NCT02753881,NCT01009801,NCT00732836,NCT01324076,NCT00003907,NCT00956930,NCT00093444 |
Malignant neoplasm of pancreasDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10 |
NCT04808687,NCT05083247,NCT02810418,NCT02017015,NCT05222204,NCT05493995,NCT04289792,NCT02301143,NCT03807999,NCT02024009
|
Neoplasms of unknown behaviour of urinary organsDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2F98 |
NCT04383743,NCT04876313,NCT02560038,NCT04506554,NCT00005831,NCT00478361,NCT03669783,NCT05024773,NCT02710734,NCT05203913
|
Diffuse large B-cell lymphomasDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A81 |
TRIM24,TOP2A,TUBB6,PMP22,AURKA,GMNN,ITGAV,EPAS1,THRB,LMNA
|
Fungal infectionDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1F29-1F2F |
RAB9A
|
Coronary thrombosisDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA43 |
F2
|
Myocardial infarctionDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA41-BA43 |
F2
|
ThrombocytopeniaDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3B64 |
F2
|
Respiratory system diseaseDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CB40-CB7Z |
TOP2A
|
LymphangioleiomyomatosisDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CB07 |
MTOR
|
Acute diabete complicationDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A2Y |
AURKA
|
Cardiovascular diseaseDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA00-BE2Z |
F2
|
ChemoprotectionDisease Category: NADisease ICD-11 Code: N.A. |
TOP2A
|
Anogenital wartsDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1A95 |
TOP2A
|
Otitis externaDisease Category: 10.Diseases of the ear or mastoid processDisease ICD-11 Code: AA00-AA13 |
TOP2A
|
Malignant mesenchymal neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B5D-2B5Y |
MTOR
|
Cerebral ischaemic strokeDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B11 |
F2
|
Angina pectorisDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA40 |
F2
|
Transplant rejectionDisease Category: 22.Injury, poisoning or certain other consequences of external causesDisease ICD-11 Code: NE84 |
MTOR
|
Urinary tract infectionDisease Category: 16.Diseases of the genitourinary systemDisease ICD-11 Code: GC08 |
TOP2A
|
Nutritional deficiencyDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5B50-5B71 |
F2
|
Chronic myelomonocytic leukaemiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A40 |
MTOR
|
Type 2 diabetes mellitusDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A11 |
F2
|
Coagulation defectDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3B10 |
F2
|
HydrocephalusDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8D64 |
MTOR
|
Common wartsDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1E80 |
TOP2A
|
Metastatic lymph node neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D60 |
MTOR
|
Stomach cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B72 |
TOP2A
|
Ischaemic/haemorrhagic strokeDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B20 |
F2
|
Arteries/arterioles disorderDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BD52 |
MTOR
|
Alzheimer diseaseDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A20 |
TOP2A
|
Gonococcal infectionDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1A70-1A7Z |
TOP2A
|
Bacterial infectionDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1A00-1C4Z |
TOP2A
|
Bleeding disorderDisease Category: 16.Diseases of the genitourinary systemDisease ICD-11 Code: GA20-GA21 |
F2
|
Hypo-thyroidismDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A00 |
THRB
|
Otitis mediaDisease Category: 10.Diseases of the ear or mastoid processDisease ICD-11 Code: AA80-AB0Z |
TOP2A
|
Hyper-lipoproteinaemiaDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5C80 |
THRB
|
SyphilisDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1A61-1A6Z |
TOP2A
|
HIV-infected patients with tuberculosisDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1B10-1B14 |
TOP2A
|
Inborn lipid metabolism errorDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5C52 |
THRB
|
IschemiaDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B10-8B11 |
NCT02835586
|
Primary neoplasms of brainDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00 |
NCT00479765
|
Malignant neoplasm metastasis in bone or bone marrowDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E03 |
NCT03678883
|
Pleomorphic adenomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH2KC1 |
NCT00502203
|
Extranodal NK/T-cell lymphoma, nasal typeDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90.6 |
NCT00725231
|
Adrenal cortical carcinomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH4KH2 |
NCT00786110
|
Type1diabetesmellitusDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A10 |
NCT01581476
|
GliosarcomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH9RC8 |
NCT04528680
|
Human immunodeficiency virus type 1Disease Category: X.Extension CodesDisease ICD-11 Code: XN8LD |
NCT01435018
|
Malignant neoplasm metastasis in female reproductive systemDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E05 |
NCT02739529
|
Other specified malignant neoplasms of oropharynxDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B6A.Y |
NCT01249443
|
Burkitt-like lymphoma with 11q aberrationDisease Category: X.Extension CodesDisease ICD-11 Code: XH8NN2 |
NCT02228772
|
Lymphoplasmacytic lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A85.4 |
NCT00801281
|
Carcinosarcoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH2W45 |
NCT00815945
|
Hypopharyngeal cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B6D |
NCT01249443
|
Choroid plexus tumoursDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00.22 |
NCT01014767
|
Malignant trophoblastic neoplasms of placentaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C75.0 |
NCT02639650
|
Verrucous carcinoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH5PM0 |
NCT01249443
|
AnemiaDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3A00-3A9Z |
NCT00189371
|
Chronic myelogenous leukaemia, BCR-ABL1-positiveDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A20.0 |
NCT01424982
|
Mesotheliomas of peritoneumDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C51.2 |
NCT05449366
|
LiposarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B59 |
NCT05218499
|
OligoastrocytomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH6F49 |
NCT02372409
|
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecifiedDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1C62.Z |
NCT01249443
|
Small cell carcinoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH0YB0 |
NCT02881125
|
Malignant neoplasms of vulvaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C70 |
NCT00014599
|
GanglioneuroblastomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH77W7 |
NCT03786783
|
Myelodysplastic syndromeDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A37 |
NCT03059615
|
Other specified carcinoma in situ of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E65.Y |
NCT01891357
|
Metastatic lung neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D70 |
NCT03678883
|
Malignant lymphoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH5FJ5 |
NCT00126243
|
Cervical intraepithelial neoplasiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E66 |
NCT03143491
|
Malignant neoplasm of liverDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.0 |
NCT01272557
|
Adult T-cell leukaemia/lymphoma (HTLV-1 positive)Disease Category: X.Extension CodesDisease ICD-11 Code: XH6TE2 |
NCT00145002
|
Mature B-cell neoplasms, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A8Z |
NCT02911142
|
Acute leukaemias of ambiguous lineageDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A61 |
NCT02419755
|
Pilocytic astrocytomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH12D2 |
NCT02372409
|
Neoplasms of unknown behaviour of female genital organsDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2F96 |
NCT02182245
|
Castlemans diseaseDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4B2Y |
NCT02228512
|
Adenoid cystic carcinomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH4302 |
NCT00581360
|
Mature B-cell leukaemiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A82 |
NCT01328236
|
Malignant neoplasms of vaginaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C71 |
NCT00002949
|
Other specified malignant neoplasms of the ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73.Y |
NCT02429700
|
NeuropathyDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8C0Z |
NCT02311907
|
Prostate hyperplasiaDisease Category: 16.Diseases of the genitourinary systemDisease ICD-11 Code: GA90 |
NCT03423979
|
Nausea/vomitingDisease Category: 21.Symptoms, signs or clinical findings, not elsewhere classifiedDisease ICD-11 Code: MD90 |
NCT02116530
|
Astrocytoma, anaplasticDisease Category: X.Extension CodesDisease ICD-11 Code: XH96C7 |
NCT02372409
|
Oligodendroglioma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH7W59 |
NCT02372409
|
Allergic/hypersensitivity disorderDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4A80-4A8Z |
NCT00277043
|
Malignant neoplasms of oropharynxDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B6A |
NCT03416153
|
Parathyroid carcinomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH7JQ0 |
NCT03181100
|
Cutaneous T-cell lymphoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH1951 |
NCT02192021
|
Actinic keratosisDisease Category: X.Extension CodesDisease ICD-11 Code: XH36H6 |
NCT03083470
|
Malignant neoplasms of anus or anal canalDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C00 |
NCT01249443
|
Neuroendocrine tumour, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH8DS0 |
NCT04602117
|
Other specified amyloidosisDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5D00.Y |
NCT00030381
|
Gallbladder/bile ducts/liver structural developmental anomalyDisease Category: 20.Developmental anomaliesDisease ICD-11 Code: LB20 |
NCT02392637
|
Diseases of the blood or blood-forming organs, unspecifiedDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3C0Z |
NCT04243434
|
Optic nerve disorderDisease Category: 09.Diseases of the visual systemDisease ICD-11 Code: 9C40 |
NCT02372409
|
Sex cord-gonadal stromal tumour, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH9G57 |
NCT01770301
|
Other specified malignant neoplasms of colonDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B90.Y |
NCT00034190
|
Diseases of the digestive system, unspecifiedDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DE2Z |
NCT00208936
|
Diseases of coronary artery, unspecifiedDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA8Z |
NCT00124943
|
Rectum cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B92 |
NCT02574663
|
Rheumatoid arthritisDisease Category: 15.Diseases of the musculoskeletal system or connective tissueDisease ICD-11 Code: FA20 |
NCT00055133
|
Teratoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH83G5 |
NCT00104676
|
Crohn diseaseDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DD70 |
SLCO1B3
|
PheochromocytomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH3854 |
EPAS1
|
Inflammatory bowel diseases, unspecifiedDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DD7Z |
SLCO1B3
|
Osteoarthritis, unspecifiedDisease Category: 15.Diseases of the musculoskeletal system or connective tissueDisease ICD-11 Code: FA0Z |
TOP2A
|
Idiopathic pulmonary fibrosisDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CB03.4 |
SLCO1B3
|
Myotonic dystrophyDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8C71.0 |
TOP2A
|
Tetralogy of FallotDisease Category: 20.Developmental anomaliesDisease ICD-11 Code: LA88.2 |
F2
|
Cytomegaloviral diseaseDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1D82 |
THRB
|
Chikungunya virus diseaseDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1D40 |
LMNA
|
Polycystic ovary syndromeDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A80.1 |
ITGAV
|
Carpal tunnel syndromeDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8C10.0 |
TUBB6
|